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ABSTRACT OF THE DISSERTATION
Nanoparticle T cell Engagers as a Modular Platform for Cancer Immunotherapy
by
Kinan Alhallak
Doctor of Philosophy in Biomedical Engineering
Washington University in St. Louis, 2021
Research Advisor: Abdel Kareem Azab, PhD
Immunotherapy is a class of treatment that stimulates a person’s own immune system to
recognize, target, and eliminate cancer cells. In recent years, immunotherapy has taken center
stage in a variety of malignancies and holds great promise in becoming the “cure” for cancer. T
cell-base immunotherapies such as chimeric antigen receptor (CAR)-T cells and T cell engagers
(TCEs) have shown promising pre-clinical and clinical results. As the field progresses with novel
strategies, the ability to manipulate the immune system with high efficiency, persistency, and
robustness, along with limited toxicities has become a major hurdle for clinical translation. To
this end, we created a new class of nanoparticle-based T cell engager (nanoTCE) platform by
combining biomaterials into immunotherapies to achieve cell-specific immunomodulation,
overcome immunosuppression, and address tumor microenvironment heterogeneity.
CAR-T cells are autologous T cells that have been virally transfected outside the body to
express an engineered CAR construct, containing a synthesized fragment that targets a desired
surface antigen on cancer cells. While this therapy produces favorable results, it is challenged by
a long list of limitations, including toxicity, high cost, complex production process, the need for
frequent quality testing, and safety concerns with the viral vector. On the other hand, TCEs are a
non-cell therapy consists of two single chain variable fragments connected by a protein linker.
One fragment recognizes a tumor-associated surface antigen, while the other recognizes the CD3
vii

receptor on a T cell. TCEs demonstrate high potency and efficacy against tumor cells and exploit
the use of endogenous T cells, circumventing the limitation of genetically engineering extracted
patient T cells to express CARs. The disadvantages of TCEs, however, include toxicity,
laborious and tedious production, the need for continuous infusion due to short pharmacokinetics
(PK), and the inability to induce persistent T cell activation. Moreover, both CAR-T and TCE
therapies target one single antigen, which confer the development of antigen-less clones, tumor
escape, and relapse, especially in multi-clonal diseases such as Waldenstrom Macroglobulinemia
(WM) and Multiple Myeloma (MM).
To address some of the limitations faced by CAR-Ts and TCEs, we developed
nanoparticle-based bispecific T cell engagers (nanoBTCEs), which are liposomes decorated with
monoclonal antibodies targeting anti-CD3 on T cells and one cancer antigen on tumor cells. We
show that nanoBTCEs 1) have a long half-life of about 60 hours, which enables once-a-week
administration instead of continuous infusion; 2) induce T cell activation in the presence of WM
and MM cancer cells; and 3) induce T cell-mediated cancer cell lysis of WM and MM cells. Due
to the nanoparticulate nature of nanoBTCEs, we improved pharmacokinetics profile compared to
regular TCEs, enabled simple and affordable production, and created an off-the-shelf platform
for cancer immunotherapy.
Furthermore, for multi-clonal diseases such as MM, we also developed nanoparticlebased multispecific T cell engagers (nanoMuTEs), which are liposomes decorated with anti-CD3
monoclonal antibodies targeting T cells, and monoclonal antibodies targeting more than one
cancer antigen. NanoMuTEs targeting multiple cancer antigens showed greater efficacy in MM
cells in vitro and in vivo, compared to nanoBTCEs targeting only one cancer antigen. Unlike
nanoBTCEs, treatment with nanoMuTEs did not cause downregulation of a single antigen and
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prevented the development of antigen-less tumor escape. To this point, our nanoparticle-based
immuno-engaging technology provides a solution for the major limitations of current
immunotherapy technologies, such as cost, PK, and tumor escape.
Another major disadvantage TCEs face is weaker T cell activation and persistence
compared to CAR-T cells, which is why CAR-T cells have a greater anti-tumor response
compared to TCEs. The small molecule phytohemagglutinin (PHA) is a commonly used to
activate T cells ex vivo. However, it hasn’t been used for immunotherapy in vivo due to its
biological instability and toxicity. We report the encapsulation of PHA in a liposome increased
its stability and reduced its toxicity in vivo, activated T cells in vitro and in vivo, and induced
killing of tumor cells in vitro and in vivo. The liposomal PHA is a new form of pan-cancer
immunotherapy which acts regardless of tumor antigens and thus does not induce antigen-less
tumor escape, while also circumventing current obstacles of T cell exhaustion.
In conclusion, our nanoTCE platform uses nanoparticles to create a relatively simple,
reproducible, and off-the-shelf solution to overcome the major limitations of current
immunotherapy techniques such as TCEs and CAR-T cells. The nanoTCE targets each antigen
with high specificity, creating a more robust immunotherapy technology to induce the immune
system for an effective response. More importantly, nanoTCE can be customized to target any
combination of desired cancer or immune cell antigen. This simple, customizable, specific,
translational, and efficacious nanoTCE platform provides the flexibility to engage any immune
cell for the treatment of the cancer of interest and can be used for personalized medicine based
on the cancer antigens presented by the patient’s tumor.
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Chapter 1: Biomaterials for Cancer Immunotherapy
1.1 Non-Cellular Immunotherapies
1.1.1 Delivery of Antibodies
Delivery of antibodies is one of the most pursued immunotherapy strategies. Many of these
antibodies bind to cancer-specific antigens to induce immune-mediated cancer killing. Some are
designed to target T cells or antigen-presenting cells (APCs) to modulate and refine their
responses, while others bridge both mechanisms to create a direct link between immune cells and
cancer cells [1, 2]. These have all received great clinical success and have led to approvals by the
U.S. Food and Drug Administration (FDA). However, the disadvantages of antibodies include:
(i) their short half-lives; (ii) poor tumor penetration; and (iii) the use of targets not unique to
cancer cells leading to off-target effects. Here, we examine some of the ways biomaterials are
used to assist and improve antibody-based immunotherapies.

1.1.1.1

Tumor-Targeting Antibodies

Antibodies targeting tumor antigens are among the earliest-studied cancer therapies. A great
number of cancer-targeting monoclonal antibodies (mAbs) have been approved by the FDA for a
variety of malignancies [2]. Therapeutic antibodies function via multiple anti-tumor mechanisms,
including antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity
(CDC), and induction of T cell immunity through cross-presentation [3]. Examples for mAbbased immunotherapy include (i) alemtuzumab (Campath®), an anti-CD52 antibody that binds
and kills leukemia cells for the treatment of B cell chronic lymphocytic leukemia (CLL) via
ADCC [4]; (ii) retuximab (Retuxan®), an antibody that binds to CD20 on B cells and eliminates
tumors via ADCC [5]; and iii) trastuzumab (Herceptin®), an anti-HER2 antibody for the
1

treatment of HER2-overexpressing metastatic breast cancer that function via inhibition of tumor
proliferation and recruitment of effector cells [6].
Many biomaterials are developed to help achieve specific and controlled delivery of
antibodies to increase the potency of the treatment. Guziewicz et al. reported the use of a
lyophilized silk fibroin hydrogel as a novel biomaterial for the stabilization and sustained
delivery of antibody therapeutics, in which the silk-antibody hydrophobic/hydrophilic
interactions prolonged the release of encapsulated antibodies for over 38 days [7]. This enabled
the antibody to better accumulate at the tumor site due to longer circulation. Additionally,
biocompatible and biodegradable mesoporous silica (SiO2) films have been explored to achieve
sustained release of anti-vascular endothelial growth factor (VEGF) mAb bevacizumab
(Avastin®) [8]. This system was able to release functionally-active antibodies and release 98% of
the drug over a period of a month. Another study developed an artificial organoid implant
comprised of a PEG-heparin cryogel scaffold to customize the release of bispecific antibodies for
immunotherapy against acute myeloid leukemia (AML) [9]. This novel cryogel scaffold
encapsulated human mesenchymal stromal cells (MSCs) which were genetically modified to
secrete anti-CD33/anti-CD3 bispecific antibodies for the activation of T cells. This device
effectively supported MSC proliferation and continuously released the bispecific antibodies
which overcame limitations of free bispecific antibodies such as their short half-lives and
systemic toxicity.

1.1.1.2

Immunostimulatory Antibodies

Another class of antibodies have been developed for the stimulation of immune cells such as T
cells and APCs. These include mAbs that function as agonistic ligands for co-stimulatory
receptors, enhance activation and/or maturation of APCs, inhibit immunosuppressive
2

mechanisms caused by cells such as regulatory T cells (Tregs), and inhibit lymphocyte inhibitory
receptors [10]. CD40 is among the most studied co-stimulatory receptors found on APCs such as
dendritic cells (DCs), B cells, and macrophages; mAbs agonistic to CD40 are known to promote
anti-tumor immunity by inducing cytotoxic T cell responses [11, 12]. However, the maximum
tolerated dose for CD40 mAb is limited due to the occurrence of inflammatory response in offtarget organs and serious systemic toxicities such as cytokine release syndrome (CRS) and T cell
depletion [13, 14]. One example of biomaterial-assisted presentation of co-stimulatory signals to
APCs was reported by Gu et al. to improve the potency of CD40 mAbs [15]. Luminescent
porous silicon nanoparticles conjugated with CD40 mAbs were able to achieve a 30-40-fold
increase of B cell activation compared to the non-conjugated nanoparticles. Another study
coupled agonistic anti-CD40 antibody with adjuvant CpG oligonucleotides onto the surface of
PEGylated liposomes for intratumoral delivery to APCs. The two agents have been tested to
demonstrate synergistic anti-tumoral effects, but the potency was concurrent with systemic
toxicity. Anchoring the two potent and synergistic agents on liposomes resulted in a high level of
retention in the tumor and surrounding tumor microenvironment (TME) [16].
4-1BB (also known as CD137) is a co-stimulatory receptor for T cell activation, and
agonistic antibodies for CD137 could generate anti-tumor immunity. However, the systemic
administration of CD137 antibody elicited disordered T cell infiltration and inflammation in the
liver [17]. To circumvent this lethal immunotoxicity, anti-CD137 and anti-IL-2 antibodies were
anchored onto the surface of liposomes, which resulted in rapid accumulation of therapeutics in
tumors while lowering systemic exposure [18]. Overall, nanoparticle-assisted delivery achieved
anti-tumor activity similar to free agents alone but without life-threatening systemic toxicities.
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1.1.1.3

Immune Checkpoint Inhibitors

Immune checkpoint inhibitors are antibodies that compromise the tumor cell’s ability to evade
immune system [19]. The first FDA-approved immune checkpoint inhibitor was the anticytotoxic T-lymphocyte antigen 4 (CTLA-4) antibody, which releases T cells from repressive
signals and activate their responses toward cancer [20]. Additionally, checkpoint inhibitors that
disrupt the “don’t kill me signal” have also taken center stage in the clinic. Inhibition of the
interaction between programmed cell death protein 1 (PD-1) on T cells and ligand (PD-L1) on
tumor cells has proven to enhance T cell response and induce antitumor activity in patients [21].
While immune checkpoint inhibitors demonstrated remarkable efficacy in a variety of cancers,
the inconsistent response rates, repeated dosing, and high toxicity profile remain to be
problematic [22].
Many approaches were reported to avoid unwanted side effects while retaining the antitumoral effects of checkpoint inhibitors. A microparticle delivery system composed of
poly(lactic-co-hydroxymethyl glycolic acid) was formulated to co-deliver CTLA-4 checkpoint
inhibitor and anti-CD40 DC-stimulating antibody [23]. The microparticles showed an initial
burst release followed by a sustained release for 30 days and showed no adverse effects.
Hydrogel-based platforms were also employed for improving kinetics for antibody release. Li et
al. reported a subcutaneously injected alginate hydrogel for dual delivery of anti-PD-1
checkpoint inhibitor and a COX-2 inhibitor [24]. The hydrogel-mediated system resulted in
higher anti-PD-1 mAb accumulation in the tumor and comparable serum concentration compared
to intraperitoneal injection of free mAb. In addition, the treatment enhanced the presence of
CD4+ and CD8+ T cells while reducing Tregs in the tumor and immune system.
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Another innovative strategy involved a biodegradable microneedle patch for sustained
local release of anti-PD-1 antibody [25]. The microneedle patch composed of hyaluronic acid
integrated with pH-sensitive dextran nanoparticles carrying anti-PD-1 antibody and glucose
oxidase, which converts blood glucose to gluconic acid. The acidic environment generated by
glucose oxidase enabled the release of anti-PD-1 from the nanoparticles and induced robust
immune response in mice melanoma models. Similar strategies have also been used to deliver
combinations of immune checkpoint inhibitors and immunosuppressive agents [25].

1.1.2 Delivery of Immunomodulators
The TME is composed of cellular components such as tumor, endothelial, epithelial, stromal, and
immune cells, as well as the non-cellular components such as the extracellular matrix. Cancer
cells alter the TME into an immunosuppressive environment and also depend on the TME for
growth, invasion, and metastasis [26]. Modification of the TME with immunomodulators such as
small molecule inhibitors, cytokines, and agonists for pattern recognition receptors (PRRs) can
be an effective strategy to enhance anti-cancer immunity [27].

1.1.2.1

Small Molecule Inhibitors

The transforming growth factor β (TGFβ) is upregulated in a number of cancer types and play a
substantial role in regulating almost every cell component in the TME [28]. Specifically, TGFβ
acts as antagonist that interferes with host immunity and is considered one of the most potent
mediators of immunosuppression in tumorogenesis [29]. Hence, TGFβ inhibitors were developed
to activate T cells and improve current chemotherapeutics. However, systemic administration of
TGFβ inhibitors can be extremely toxic owing to the central role of this signaling pathway.
One study aimed to augment T cell function inhibiting TGFβ in particular immune cell
subsets [30]. PLGA/PEG nanoparticles carrying TGFβR1 inhibitors were targeted to CD8+/PD5

1+ T cells and resulted in delayed tumor growth and prolonged survival in mice models, whereas
free TGFβR1 inhibitors had no effect. Nano-scale liposomal polymeric gels were also developed
for co-delivery of hydrophobic TGFβ inhibitors and hydrophilic IL-2 cytokines for activation of
melanoma-specific T cell responses [31].
The STAT3 transcription factor is a key immune suppressor that inhibits DC maturation
and macrophage function by suppressing antigen presentation and costimulatory molecules, as
well as promote proliferation of Tregs that inhibit cytotoxic CD8+ T cell responses [32].
Targeting STAT3 signaling has been proven to be successful in restoring cancer immunity.
Novel tumor-targeting liposomes loaded with a STAT3 inhibitor was developed by Liao et al
[33]. It was demonstrated that systemic administration of these targeted liposomes resulted in
priming of the immune system for an antitumor response, demonstrated by an increase in
activated T cells, M1-like macrophages, and DCs in the surrounding TME. This strategy also
primed the immune system for a better response against a HER2 DNA vaccine [33].

1.1.2.2

Cytokines

Cytokines are proteins that act as mediators for intracellular signaling to regulate homeostasis of
the immune system [34]. Cancer immunotherapy using cytokines is highly desirable for
engaging immune response against cancer, and the three main types are interferons (IFNs),
interleukins, and granulocyte macrophage colony-stimulating factor (GM-CSF). IFNs are known
to elicit immune responses by inducing the maturation of macrophages, natural killer (NK) cells,
T cells, and DCs [35]. IFNα-2a, IFNα-2b are the first FDA-approved cytokine-immunotherapy
for the treatment of hairy cell leukemia [36]. IFN-γ has been shown to recruit macrophages to the
TME and inhibit macrophage polarization towards the M2 tumor-associated phenotype [37].
Interleukins are known to strongly stimulate T cell proliferation and differentiation. IL-2 is
6

produced mainly by CD4+ T cells and can promote the cytolytic effects and proliferation of T
and NK cells, and was the first effective immunotherapy for cancer [38]. IL-12 is known to
induce the production of IFN-γ, promote Th1 immune response, and stimulate both the innate
and adaptive immune systems [39]. Finally, GM-CSF stimulate immune responses by promoting
T cell survival and DC differentiation and antigen presentation [40].
Cytokines administered in vivo have poor half-lives and generate severe systemic
toxicities, thus limiting their use in the clinic. Therefore, biomaterials have been employed to
circumvent this problem. One simple biomaterial application to cytokine delivery is PEGylation
for prolonged circulation. Conjugation of PEG to cytokines such as granulocyte colonystimulating factor (G-CSF), IFN -2a, IFN -2b are FDA-approved [41]. Other than PEGylation,
several polymers have been conjugated to cytokines for protection and enhanced delivery.
Polyoxazolines of various molecular weights have been reported for conjugation to G-CSF for
increased stability and safety [42].
A novel delivery platform was reported for slow and sustained release of IL-12 from
cholesterol-bearing pullulan-based hydrogel nanoparticle, which lead to prolonged IL-12
concentration in the serum without causing serious toxic events [43]. Additionally, Wang et al.
developed a system for targeted delivery of IL-12 to the TME via pH-responsive polymeric
nanoparticles, which resulted in a release of IL-12 in the acidic tumor site and subsequent
shifting of macrophages from M2 to M1 phenotype, with negligible cytotoxicity [44]. Another
study developed an injectable polymeric system composed of gelatin and chondroitin-6-sulfate
for localized and sustained delivery of IL-2 to the brain tumor [45]. Active IL-2 was released for
2 weeks in vitro and 21 days in vivo. The intratumoral treatment induced immunologic memory
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and protected 42% of the animals from tumor rechallenge, suggesting that the novel release
system is able to confer lasting antitumor immunity.
Sun et al. developed a TME-responsive nanocarrier for cell membrane-targeted delivery
of a particular cytokine, TRAIL, to maximize delivery to the membrane bound receptor and
minimize the internalization of the carrier [46]. The TRAIL-loaded DNA nanostructures
transformed into nanofibers after liposome shell degradation, and the micro-scaled nanofibers
efficiently presented the loaded TRAIL to death receptors on the cancer cell membrane and
amplified the apoptotic signaling with reduced TRAIL internalization.

1.1.2.3

Agonists of Pattern Recognition Receptors

PRRs are known to be critical costimulatory receptors on innate immune cells that play an
important role in initiating inflammatory response in myeloid cells such as macrophages and
DCs [27]. They mediate the initial sensing of infection through recognition of pathogenassociated molecular patterns (PAMPs) and endogenous damage-associated molecular patterns
(DAMPs) [47]. One important family of PRRs is the Toll-like receptors (TLRs), which is
responsible for sensing invading pathogens at the cell surface or within intracellular endosomes
and lysosomes [48]. TLR ligands can induce anti-tumor efficacy through activation of
phagocytosis and antigen presentation by myeloid cells in the TME, which could serve as a
promising cancer therapy strategy. However, systemic administration of TLR ligands may
induce nonspecific stimulation of the immune system and the inflammatory toxicities limit the
clinical application of such agents [49]. Biomaterials-based delivery strategies could protect TLR
ligands from nuclease degradation and minimize toxicities.
An agonist for TLR9 has been identified to exhibit therapeutic potential in cancer
treatment, by producing pro-inflammatory cytokines and inducing T cell responses; biomaterial8

based strategies have been used for the delivery of this agonist [50]. Cationized gelatin-based
nanoparticles loaded with a TLR9 agonist were targeted to the lymph nodes, where they
selectively bound to APCs, delivered the TLR9 agonist, and mediated local immune stimulation
[51]. In another study, novel self-assembled DNA immune-nanoflowers were used to deliver a
TLR9 agonist to macrophages [52]. These nanoagents demonstrated high potency in triggering
activation and proliferation of immune cells and secreted immunostimulatory cytokines such as
TNFα and IL-6. The TLR7/8 agonist imidazoquinoline (IMDQ) is another molecule that directs
potent cytotoxic T cell activity and induces high levels of type I IFN and IL-12. Nuhn et al.
reported a pH-degradable IMDQ-ligated hydrogel nanoparticle for delivery of IMDQ specifically
to the lymph nodes, thus dramatically reducing systemic toxicities [53].

1.1.3 Delivery of Other Molecules
1.1.3.1

Engineered Protein Scaffolds

Therapeutic antibodies are challenged by low tissue penetration especially in solid tumors due to
their large molecular weights (~150 kDa), which limit their potential for effective
immunotherapy. A wide variety of engineered protein scaffolds have been developed recently to
overcome drawbacks in mAbs. These non-immunoglobulin family protein structures are
equipped with antibody binding sites but are much smaller in size (2-20kDa) and more stable at
high temperatures [54].
One example of engineered protein scaffolds include designed ankyrin repeat proteins
(DARPins), a 12-19kDa molecule that is flexible in target design and is inexpensive to produce
[55]. Several DARPin drugs are in clinical trials, one of which is in a phase 2 trial for multiple
myeloma (MM) and works to reverse drug resistance toward front-line chemotherapy drugs
(NCT03136653). The smallest of the protein scaffolds are the bicyclic peptides called bicycles,
9

which are only 2 kDa, and are designed for quick and efficient delivery of tumor-killing toxins.
The short half-life of bicycles could be advantageous or problematic depending on the desired
goal. Pollaro et al. recently developed a bicycle peptide conjugated to an albumin binding tag,
which resulted in a long plasma half-life and deep tissue penetration [56].

1.1.3.2

Bispecific T cell Engagers

Bispecific T cell engagers (BTCEs) represent a new class of cancer immunotherapeutic. They are
tandem single chain variable (scFv) fragments connected by flexible linkers, with one scFv
specific to a T cell-specific molecule such as CD3, while the other is specific to a tumorassociated antigen (TAA), allowing BTCEs to directly link the T cell to a tumor cell, leading to
T cell activation and tumor killing, without the need for antigen presentation or stimulatory
signals [57]. Additionally, BTCEs can be used as an “off-the-shelf” product since they are not
restricted to major histocompatibility complex (MHC) molecules and are easily scalable.
The most established BTCE is blinatumomab, which simultaneously targets CD3 and the
TAA CD19 [58]. Early blinatumomab clinical trials for patients with B-lineage acute
lymphoblastic leukemia [59] and non-Hodgkin’s lymphoma [60] evidenced favorable results.
Following the use of blinatumomab, it resulted in a significantly higher median survival
compared to traditional chemotherapy [61]. Goebeler et al. concluded that a continuous injection
for 4-8 weeks, due to its short half-life, led to a more effective treatment [60]; however,
continually injecting treatment for long periods of time leads to patient discomfort and infections
which oftentimes lead to death [62]. The continual injection of BTCEs in the clinic is one of its
major clinical disadvantages. Additionally, a reoccurring theme was the neurological adverse
effects associated with blinatumomab, which was seen in a majority of clinical studies [59, 60].
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1.2

Artificial Cellular Immunotherapies

The pursuit of T lymphocytes for immunotherapy is due to their roles in tumor infiltration and
effector cell retargeting [63]. To enhance the activity of the immune system, new strategies are
explored for efficient stimulation of antigen-specific immune cells. While recent advances in
adoptive T cell therapy (extraction, modification, and infusion of autologous T cells) has led to
many successes in the clinic, the cost and efficiency of such therapy are major hurdles and limits
its potential [64, 65]. These shortcomings animated the effort to create artificial cells for more
effective cancer treatment to better understand of immune behavior [66]. Artificial immune cells
can be developed into an “off-the-shelf” product with much shorter production timeline, while
allowing better control for antigen presentation and immune activity.

1.2.1 Artificial APCs
In vivo, endogenous APCs are oftentimes restricted in antigen presentation due to
immunosuppression from the TME [67]. Artificial APCs (aAPCs) mimic the functions of APCs
to rapidly activate and expand T cells ex vivo or in vivo for cancer therapy. Cellular aAPCs have
been created from human leukemia cell lines, Drosophila cells, and mouse fibroblasts [66, 68].
While these are physiological in nature, they all require genetic modifications and potentially
carry negative regulatory molecules.
Synthetic aAPCs are emerging as an attractive tool for T cell stimulation. These
engineered particles are often comprised of lipids, polymers, or inorganic materials, and include
three signaling components required for T cell activation, including (i) pMHC–antigen
multimers, (ii) antibodies binding to stimulatory receptors (such as anti-CD28 antibodies), and
(iii) stimulatory cytokines (such as IL-2) [69]. Development of aAPCs have focused on the
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induction of CD8+ cytotoxic T cells (CTLs) via MHC class I stimulation, since these cells are
capable of antigen-specific cancer cell destruction and prolonged memory.

1.2.1.1

Spherical aAPCs

Several biomaterial-based, cell-sized, spherical aAPCs have been created to mimic and study the
interaction between APC and CTLs. Many studies have been done to determine the optimal size
and the fewest components necessary on these synthetic particles without compromising
function. One study explored the use of aAPCs made from latex microbeads (5-6 µm) conjugated
with H-2Kb-Ig/TRP2 peptide complexes, anti-CD28 antibody, 4-1BB, and CD83 ligands for the
rapid expansion of melanoma-specific CTLs [70]. These aAPCs successfully retained CTLs’
antigen-specificity toward TRP2-expressing melanoma and mediated an effective anti-cancer
response. Similar latex-based aAPCs coated with human leukocyte antigen (HLA)-A2/pIL13Rα2 complexes, anti-CD28 antibody, and CD83 molecules were used to induce CTLs reactive
to HLA+/IL-13Rα2+ glioma cells [71].
Polystyrene-based aAPCs are fairly common as well. aAPCs coated with HLA/HA-1
peptide complexes and costimulatory anti-CD28 antibodies on 5.6 µm-diameter polystyrene
beads were designed to target the expansion of HA-1 specific CD8+ effector memory T cells for
the treatment of relapsed leukemia[72]. The ease of preparation and stability of such aAPCs can
allow for several rounds of CTL expansion; a similar study using HLA-coated aAPCs were able
to maintain primary CTLs for more than 2.5 months in culture [73]. Systematic nano-engineering
approaches have also been applied to the design of aAPCs [74]. Hickey et al. reported
superparamagnetic iron oxide nanoparticles-based aAPCs conjugated with pMHC- and antiCD28 antibody to model the interaction between APCs and T cells [75]. It was reported that the
size of the aAPCs and stimulatory molecule are as important as ligand availability in achieving T
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cell activation, and that particles larger than 300 nm and greater TCR-MHC clustering resulted in
higher T cell activation.
Although bead-based aAPCs are homogeneous and easy to manufacture, the rigid and
solid structure does not allow for the dynamic remodeling that establish the immune synapse
between natural APCs and T cells, neither does it incorporate the release of cytokines [69].
Certain biomaterials were pursued to overcome this limitation. Liposomal formulations have
been explored due to their desirable properties for elevated T cell activation such as membrane
fluidity and surface nanoclusters reorganization [76-78]. However, lipid-based particles suffered
from relative instability comparing to bead-based aAPCs. Mechanically soft elastomer
poly(dimethyl siloxane) (PDMS) was also used to fabricate APCs [79]. Softer microbeads
conjugated with activating ligands were found to induce higher T cell activation compared to
rigid polystyrene beads. Degradable polymers such as poly(lactic-co-glycolic acid) (PLGA) was
also utilized to create antigen-presenting microparticles, which included recognition and costimulatory ligands conjugated on the surface and IL-2 encapsulated in the biodegradable core
[80]. This platform allowed for control over a wide range of particle sizes, sustained release of
cytokine factors, and enhanced antigen presentation of modular signals on the aAPC surface.

1.2.1.2

Nonspherical aAPCs

In addition to ligand density and co-stimulatory signals, the area of contact between the T cell
and artificial surface is also a crucial parameter for the design of synthetic aAPCs [74]. Although
nanoscale aAPCs may have advantageous properties for in vivo applications such as improved
draining to lymph nodes and reduced accumulation in the reticuloendothelial system, studies
have found that larger particle sizes (4-5 µm) provide optimal APC function [13, 75]. Another
consideration for area of contact is the shape of aAPCs. Most aAPC systems use spherical
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particles to stimulate T cells, while natural APCs are not spherical. With activation, APCs (such
as DCs) undergo major changes in cell morphology, leading to significant increases in their
overall cell surface area, facilitating interaction with T cells to direct T cell fate [73]. Therefore,
the use of nonspherical microscale particles for the design of aAPCs have generated great
interest, due to improved mimicry of endogenous interaction with T cells compared to the
spherical alternatives [74].
Ellipsoid PLGA-based aAPCs have been explored and found to lead to significant
difference in T cell stimulation compared to spherical formulations; specifically, T cells were
observed to migrate to and interact preferentially with the long axis of the ellipsoidal aAPCs,
suggesting the altered shape of aAPCs elicited higher binding efficiencies with T cells [81].
Additionally, Fadel et al. have developed single-walled carbon nanotubes (SWNT) for
facilitation of greater surface area and modifications [82, 83]. Anti-CD3 coated SWNT activated
T cells, released IL-2, and was proven to be more efficient comparing to antibody coated
polystyrene aAPCs or CD3 mAbs alone. Moreover, the functionalized SWNT preferentially
clustered to form 5-6 micron large-scale aggregates, resulting in even higher surface area for T
cell interaction and activation.

1.2.2 Artificial T cells
T cells are formidable components of the immune system that are responsible for the killing of
tumor cells. However, the TME suppresses T cell activity and many studies have shown that
CD8+ cytotoxic T cells reflect “tumor ignorance” and are unable to perform effector functions
even when presented with increasing tumor antigen [84]. Efforts are being made to produce T
cells with directivity toward target cancer cells. While engineering T cells is a promising
strategy, considerable toxicities can be generated due to CRS, macrophage activating syndrome,
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and neurotoxicity [85-87]. To circumvent these challenges, other strategies have been explored
to create artificial T cells of various constructs.
A team in UCLA reported a novel class of artificial T cells capable of boosting a host's
immune system by actively interacting with immune cells through direct contact [88]. These
artificial cells are composed of super-soft alginate microparticles that mimic the
mechanobiological features of natural T cells. The particles are also adjusted for elasticity with
calcium ions, and to mimic the biologic properties, the artificial cells are coated with
phospholipids, conjugated with CD4 signalers, and loaded with IL-2 and IFNγ. Another strategy
for engineering T cells involve attaching drug-loaded carriers to the membrane of T cells,
enabling the direct delivery of cytokines. One publication reported the conjugation of cytokineloaded liposomal nanocarriers onto the surface of transplanted T cells, which enabled the direct
delivery of cytokines to the T cells [89]. Compared with mice treated with free cytokines, this
strategy led to rapid T cell expansion at the tumor site and enhanced survival of mice melanoma
model. Engineering non-immune cells to have the machinery of T cells is another strategy for
artificial T cells. A study by Kojima et al. reported modification of human adipose stem cells
with three signaling components to mimic the complex signaling within T cells [90].

1.3

Adoptive Cell Therapy

Aside from using protein- and polymer-based materials, cell-based materials have also been used
to reach new limits for cancer immunotherapy. Adoptive cell therapy (ACT), an emerging
technique for expanding, engineering, and/or activating autologous or allogeneic immune cells
ex vivo, has received high praise for its ability to confer curative responses to patients with
advanced, refractory, or relapsed tumors. Herein, we review and discuss the ACT techniques
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used for each immune cell type (T cells, NK cells, macrophages, and DCs and the advances of
each).

1.3.1 T Cells
1.3.1.1

Tumor-Infiltrating Lymphocytes

The idea of manipulating T cells as one of the first ACT strategies and biomaterials for cancer
immunotherapy sprouted following the discovery of the T cell’s ability to often exterminate
hematological malignancies and harm recipient tissue via the graft-versus-leukemia (GvL) and
graft-versus-host disease (GvHD) effects, respectively [91]. Massive strides in T cell biology,
reprogramming, and engineering have permitted the extensive use of T cells for therapeutic
purposes. The very first adoptive transfer of T cells included the extraction of tumor-infiltrating
lymphocytes (TILs) from the suppressive TME of melanoma patients [92]. The TME is
commonly filled with tumor-specific T cells that are exhausted and insufficiently activated;
hence extracting, expanding, stimulating, and infusing these TILs back into patients creates a
living biomaterial for the use in ACT. ACT using TILs is achieved by growing them in culture in
the presence of tumor cells; once the TILs eliminate the melanoma cells, indicating the fact that
the T cells present are tumor-specific, IL-2-containing medium is then used to activate and
expand the TILs for infusion back into the patient [93]. This technique has been used for decades
[94] and has greatly succeeded in the clinical setting. About 50% of melanoma patients were
observed to have favorable response rates following the adoptive transfer of autologous TILs
[95, 96]. Current efforts are being put towards the optimization of the TIL therapy, such as the
use of lymphodepleting chemotherapy options to enhance the cytotoxic activity of the TILs and
shortening the T cells’ time in culture to prevent the induction of senescence [97].
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1.3.1.2

T Cell Receptor-Engineered T Cells

The ongoing problem, however, associated with the use of TILs is the inability to expand the T
cells found in the TME to a sufficient number of cells for the use in ACT. Alternatively, T cells
can be isolated from the peripheral blood and transduced with T cell receptor (TCR) genes that
are reactive to TAAs, enabling the conversion from naïve to antigen-specific T cells [98].
Generally, the TCR identifies the tumor antigen by binding to the antigenic peptide and MHC
present on the tumor cell surface. In this case, the newly-endowed specificity of the TCR confers
the ability of the T cell to induce cytotoxicity specifically to the cells with the targeted protein
via MHC complex I. Various TAAs have been targeted by TCR-engineered T cells such as
MART-1, gp100, CEA, p53, MAGE-A3, and NY-ESO-1 [98-103]. A problem with the initial
approach of these TCR-engineered T cells is that the targets on the cancer cell were
predominantly also present on normal tissue which, of course, lead to significant toxicities. For
instance, when Johnson et al. used TCR-engineered T cells to target MART-1/gp100, the treated
patients experienced significant hearing loss and uveitis [100]. In addition to severe toxicities, a
weakness of TCR-engineered T cells is its restriction to only targeting MHC molecules when it
is evidently known that cancer cells downregulate these MHC components [104].

1.3.1.3

Chimeric Antigen Receptor T Cells

In light of this, chimeric antigen receptor T (CAR-T) cells were created to bind to the cancer
antigen independent of the MHC. CARs are recombinant fusion proteins that are derived from
the domains of 1) the targeted antigen, 2) T cell activation (CD3), and 3) costimulatory signals
(e.g. CD28, 4-1BB, OX40, and ICOS) [105]. The very first CAR only contained CD3 and the
targeted antigen to allow for T cell activation and specificity to tumor cells, respectively.
However, the lack of persistence and expansion of T cells during therapy lead to the addition of
costimulatory domains into the CAR [106]. Additive effects were seen when multiple
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costimulatory molecules were put onto the CAR vector [107]. These CAR vectors are derived
from viruses to take advantage of its transduction machinery. To create CAR-T cells, blood is
first collected from the patient and purified for T cells; these T cells are then activated and
expanded with beads covered with CD3 and CD28 antibodies [108]. While these T cells are
being activated and expanded, the viral vector with the desired CAR proteins are incubated with
the cells and removed after multiple days of incubation. Due to the ability of the vector to present
the CAR in the form of RNA [109], this enables the cargo to be entirely integrated within the
phenotype of the T cell. When these cells are injected back into the human body, they
continually proliferate and lyse their targets, hence creating these “living drugs” for the treatment
of cancer (~$500,000 per treatment) [110].
Huge success has been seen with CAR-T therapy for the treatment of hematological
malignancies. The first type of CAR-T therapy was used to target CD19 on neoplastic B cells
[111]. Other CAR-T targets used for non-Hodgkin lymphoma (NHL), HL, AML, and MM
include CD20, CD30, CD33, and BCMA, respectively [112-115]. With the use of this ACT,
however, a major complication that arises is CRS, which is an adverse event resulting from a
bulk release of cytokines largely orchestrated by macrophages [116]. Complications typically
seen for CRS include hypotension, fever, nausea, tachycardia, respiratory insufficiency, among
others [117].
Another prohibitively complex aspect of creating CAR-T cells is the ability to only target
and kill the cancer without killing each other especially for the treatment of T cell malignancies.
To circumvent this issue, a group from the Washington University School of Medicine has
created an “off-the-shelf” CAR-T for the treatment of T cell malignancies [118]. Cooper et al.
deleted CD7, which is present on both healthy and malignant T cells, from the T cells that were
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equipped with the CD7-targeting CAR vector to prevent the CAR-T cells from killing each
other. Another study successfully deleted the endogenous TCR and HLA class I from the CAR-T
cells for the “off-the-shelf” use in cancer therapy [119].
Compared to hematological disorders, solid tumors have not seen much success with
CAR-T cell therapy due to the overwhelming variety of immunosuppressive cells existing in the
TME such as tumor-associated macrophages, Tregs, and myeloid-derived suppressor cells. A
creative strategy that potentiates the effect of CAR-T therapy is the use of polymer implants to
locally deliver the CAR-T cells to the tumor [120, 121]. However, more strategies are warranted
for the enhancement of CAR-T cell therapy for solid tumors.

1.3.2 Natural Killer Cells
NK cells have also been used as a living drug and biomaterial for ACT. NK cells are very similar
to T cells in the sense that both secrete very similar effector molecules such as perforin,
granzymes, and IFN. One advantage of using NK cells compared to T cells for ACT is the
ability to avoid GvHD with the use of allogeneic NK cells. NK cells do not attack normal cells
due to the MHC class I molecules expressed on the normal cells; these molecules inhibit the
cytotoxic effects of NK cells by binding to the inhibitory killer immunoglobulin-like receptor
(KIR) on the NK cells [122]. On the other hand, for the cells that do not express sufficient levels
of MHC class I molecules, the NK cell triggers its activating signals which in turn eliminates the
target cell. For example, clinicians have taken advantage of this scenario by taking these
alloreactive NK cells and infusing them into patients with refractory AML [123]. In this study,
the NK cells protected the patients from relapse due to the lower expressions of MHC class I on
the AML blasts. Patients with other cancer subtypes such as melanoma, renal cell carcinoma, and
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HL were investigated and showed favorable results with NK cell therapy as well [123]. Despite
the absence of MHC class I molecules on tumor cells, NK cells oftentimes do not recognize the
tumor.
To aid the NK cells with specificity towards TAAs, NK cells have also been manipulated
with the CAR approach. CAR-NK targets used for MM, NHL, and melanoma include CS1,
CD20, and GPA7, respectively [124-126]. In contrast to CAR-T cells, CAR-NK cells are able to
be “off-the-shelf” for use in cancer treatment. NK-92, an immortal NK cell line, has shown
clinical efficacy for ACT [127] and has recently concluded a pre-clinical study using NK-92
cells transduced with a CAR vector for triple-negative breast cancer [128]. Scientists using ACT
with NK cells have also pursued functionally-activating these cells with interleukins (e.g. IL-12,
IL-15, and IL-18) prior to re-infusion in vivo [129] and have instigated a clinical trial for the
treatment of AML (NCT01898793) based on the ability of the pre-clinical study to confer
memory-like NK cells.

1.3.3 Macrophages
To this day, the treatment of solid tumors remains to be a major obstacle for the field of cancer
immunotherapy. The most abundant immune cells found in the TME are myeloid cells.
Macrophages, a specific lineage of myeloid cells, are APCs that phagocyte pathogens and
infectious agents and present the acquired antigens to activate naïve T cells. Tissue homeostasis
is mediated by macrophages and these cells have also been found to have an ambiguous role in
the homeostasis of the tumor [130]. In light of this, extensive investigation has been pursued on
macrophages for the use in ACT. In 1985, Stevenson et al. were the first to grow and activate
monocytes, the precursor to macrophages, ex vivo with IFN
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prior to re-infusion for the

treatment of colon cancer [131]. More recently, a clinical protocol has been published for the use
of autologous monocytes for the treatment of ovarian cancer [132].
Another recent approach to increase the specificity of the macrophages to tumor cells is
using CAR-Macrophages (CAR-MA); this technique potentiates the effect of CAR therapy for
the treatment of solid tumors due to the high quantities of macrophages infiltrating the TME and
the ease of acquiring them. The first group that used CAR-MA only demonstrated the ability of
the cells to phagocytose CD19- or CD20-coated silica beads when transduced with the CAR
vector in vitro [133]. In this study, the investigators used the cytosolic domains of Megf10 to
trigger phagocytosis. Dr. June and colleagues, on the other hand, have also created CAR-MA by
utilizing the HER2-targeting CAR vector in the CD3 receptor of the macrophage [134]. Like the
CAR-NK cell therapy, CAR-MA also act as “off-the-shelf” products for cancer treatment.

1.3.4 Dendritic Cells
A major function of DCs is the cross-presentation of exogenous antigens and presenting these
antigens to CD4 and CD8 T cells via MHC class II and I molecules, respectively [135].
Stimulating T cells via cross-presentation allows the DCs to be the most potent and efficient
APCs in the human body [136]. Taking advantage of the putative role of DCs, multiple research
groups have pursued this cell type for ACT. Porgador et al. were the first to show the proof of
concept of “educating” the DCs prior to re-infusion in vivo [137]. The autologous DCs were
incubated with the desired tumor antigen peptide to enable engulfment of the antigens and
facilitate T cell immunity when injected back in vivo. Cytokines have also been combined with
tumor peptides during ex vivo DC activation. GM-CSF, IL-2, and IL-4 have all been combined
individually with peptides to aid in DC stimulation in clinical trials [138-140].
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Another successful approach demonstrated by others utilizes the transduction of DCs
with viral vectors ex vivo. The primary rationale of transducing DCs with viruses outside rather
than inside the body is due to the humoral immune system to secrete neutralizing antibodies
following the treatment of adenoviruses [141]. Furthermore, DCs transduced ex vivo have shown
greater than 95 percent efficiency following viral transfection [142] and have been used in
clinical trials for patients with cancers such as renal cell and prostate cancer [143]. Squadrito et
al. have recently shown the introduction of chimeric receptors in the form of a viral vector to
enhance the uptake of tumor microvesicles of DCs and induce high tumor efficacy for the
treatment of breast cancer [144]. Ex vivo stimulation of DCs with these techniques have been
used in cancer patients for more than a decade and are currently rendering favorable responses
and complete remissions [145].

1.4

Gene-Based Immunotherapies

1.4.1 Small Interfering RNA
Regulating gene expression using small interfering RNA (siRNA) is a highly used technique in
the field of cancer immunotherapy. siRNA is specifically used to knockdown a gene for a short
period of time. These siRNAs undesirably activate the immune system when injected into the
human body in its naked form [146] and are recognized by immune cells via the TLRs [147].
Many have taken advantage of the double-edged sword tactic of immune stimulation and utilized
it for cancer immunotherapy. For instance, one study silenced a drug resistant-associated gene
with a siRNA in melanoma, upregulated IFN , and induced the stimulation of DCs via TLR7
for cancer treatment [148]. In addition, a siRNA was used against human papillomavirus (HPV)driven tumors and seen to concomitantly induce an innate immune response via TLR7 and TLR8
[149]. These studies have proven to treat malignancies without actually targeting the immune
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system, which provides strong evidence of the multifaceted approach of siRNAs for cancer
immunotherapy. However, many challenges exist following the systemic administration of naked
siRNA such as its tendency to upregulate the immune system and not alter tumor fate, nonspecificity, and low stability [150]. Therefore, current and ongoing siRNA modalities are
pursuing established methods for the safe delivery of siRNA including its encapsulation in viral
vectors or nanoparticles.
Additionally for gene-silencing treatment to function correctly, the siRNA must enter the
cytoplasm of the cell and avoid exocytosis [151]. In fact, around 70% of lipid nanoparticles
encapsulated with siRNA have been shown to be excreted by the cell, requiring a more creative
method of enclosing siRNA to increase efficiency [152]. Polyethylenimine nanocapsules
encapsulated with PD-L1 siRNA have been used to successfully reprogram tumor-associated
DCs to induce tumor efficacy [153]. The siRNA polymeric particles were intentionally used for
the engulfment by both the DCs and the cancer to enable a change in phenotype and an increase
in immunogenicity, respectively. In another case, siRNA particles were used to silence the
chemokine receptor CCR2 on monocytes, decreasing the number of tumor-associated
macrophages in the TME [154]. siRNA molecules have also been conjugated to metal
nanoparticles for the use in biomaterials for cancer immunotherapy. These metal particles were
targeted to silence VEGF in tumor-associated macrophages and lung cancer cells in vivo [155].
The incorporation of siRNA is not just limited to nanoparticles; one study entrapped an siRNA
against IL-4 and mammalian target of rapamycin (mTOR) in a polyethylene glycol (PEG)-based
hydrogel for the potential localized treatment of cancer and induce, for instance, macrophage
polarization [156].
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An interesting approach also pursued was the ex vivo silencing of a gene in tumor cells
and subsequently injecting these tumor cells back into the patient in a Phase I clinical trial [157,
158]. This siRNA was put into a viral vector and transfected into the patient’s tumor cells to
prevent the production of an immunomodulatory cytokine, TGF . Following transfection, the
tumor cells were then irradiated to ensure the growth cycle arrest of these cells. The treated
patients lived significantly longer than the non-treated patients [158], hence suggesting further
investigation for this type of treatment option. However, a couple of disadvantages exist for the
use of siRNA knockdown for cancer immunotherapy. siRNA therapy only knocks down the
target gene for 24-72 hours following transfection and the efficiency of this knockdown varies
tremendously per gene. Therefore, a greater number of therapeutics reprogramming tumorassociated immune cells and restoring tumorigenic cytotoxicity for cancer treatment is highly
warranted.

1.4.2 Messenger RNA
1.4.2.1

mRNA Use in DCs

Another way of modulating gene expression in cells is the introduction of messenger RNA
(mRNA) to the cell with the gene of interest. Specifically, mRNA augments the desired
concentration of protein in the cell, whereas siRNA induces the opposite and silences the gene
for the attenuation in protein expression [159]. APCs have been targeted to induce an immune
response with mRNA therapy. As mentioned with siRNA, naked mRNA is also degraded very
quickly when injected in the human system and needs to reach the cell cytoplasm for protein
translation [160]. Mounting evidence is accumulating for the use of mRNAs in cancer
immunotherapy. One instance demonstrates the use of mRNA-conjugated protamine for the
induction of TLR7 to induce anti-tumor activity in vitro and in vivo [161]. Another study exhibits
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the use of a mRNA-cationic peptide complex for the stimulation of DCs, in particular, via TLR7
[162]. Conjugating mRNA to a cationic peptide deters the premature degradation of the mRNA
complex.
The ex vivo stimulation of DCs has been pursued with the use of mRNAs and allows the
precise manipulation of the antigens desired on DCs. In particular, Langerhans-like DCs were
transfected ex vivo with mRNAs encoding the desired antigens onto these cells for both MM and
melanoma in patients [163]. However, these cells are not available in large quantities and
expanding these cells requires extensive protocols and expensive facility equipment for the
treatment of these patients. Different techniques have been used for the delivery of mRNA to
DCs such as nucleofection, electroporation and sonoporation [164-166] due to the amenability of
the DCs. These DCs have been further improved by inducing immunostimulatory cytokines such
as IL-12 and IL-18 using mRNAs [167, 168]. This would allow NK cell activation, CD4
differentiation, and induce effector molecule secretions by T cells. In addition, mRNAs coding
for PD-1, PD-L1, anti-CTLA-4, or anti-GITR have been investigated in DCs [169-171]. In this
case, rather than using mAbs to inhibit immune checkpoints, the authors transfected DCs to
express these ligands to block their respective receptors. The success of this approach led to the
initiation of a clinical trial utilizing mRNAs coding for anti-CTLA-4 [163]. The process includes
the extraction of DCs, incubation with the desired mRNA, and injection intranodal to the
patients. A pre-clinical study used a combination of mRNAs encoding CD70, CD40 ligand, and
TLR4 for the enhanced stimulation of DCs [172]. Specifically, the DCs, once transfected,
generated cytotoxic T cells and converted regulatory to helper T cells. Following this study, a
clinical trial was pursued with stage III and IV melanoma tumors and showed to induce an
objective response rate of 27% [173].
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1.4.2.2

mRNA Use in T Cells

With regards to CAR-T cells, the creation and regulation of viral vectors are complex and
expensive. Many groups are trying to make the CAR-T development process more efficient and
have begun electroporating T cells with mRNA to encode CAR proteins to circumvent the issues
of viral vectors. In this case however, mRNA transfection is only transient and is unable to
integrate into the genome of the T cell [174]. Therefore, CAR mRNAs render the T cells as a
short-term treatment and are currently under investigation in clinical trials [174]. Creating shortlived CAR-T cells alleviates the problem of the off-tumor toxicity that is typically seen with
CAR-T cell therapy; adverse events include tumor lysis syndrome and anaphylaxis. mRNAtransfected CAR-T cells alleviated the symptoms associated with anaphylaxis in a clinical study
[175]. As mentioned in the study, CAR therapy with mRNA transfection lack persistence and
potency; Foster et al. have shown that purification and modification of the mRNA renders robust
T cell responses [176]. The T cells electroporated with the modified mRNA constructs enabled a
100-fold decrease in tumor burden compared to the T cells with unmodified mRNA.
Other methods of producing CAR-T cells includes the incubation of extracted T cells
with mRNA-encapsulated nanoparticles [177]. Previous methods of producing CAR-T cells
require electroporation in order for the CAR-encoding mRNA to reach the cytoplasm. The
mRNA particles, on the other hand, are conjugated with anti-CD3 and anti-CD8 to target the T
cells and stimulate endocytosis. One study has successfully demonstrated the delivery of
immunotoxins using T cells to the tumor via mRNA transfection [178]. Due to the inability of
drugs to home to the tumor cells, hence T cells were transfected to secrete the particular
immunotoxin that inhibits cancer cell growth and used to home to the tumor. Neoantigens, newly
formed antigens only present on the surface of cancer cells, are very precise and specific targets
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for the use in mRNA vaccines. Cationic lipids complexed with mRNA was injected
intravenously and was seen to primarily induce CD4 T cell responses [179].

1.5

Conclusions

In summary, immunotherapy has emerged and established itself as a major pillar for curative and
palliative care for cancer treatment. However, these therapies have many limitations and are in
need of improvement. A range of protein-, polymer-, and cell-based materials have been
implemented in the clinical setting as novel strategies to better target and treat multiple cancer
subtypes while also minimizing the side effects associated with treatment. With the ability to
customize biomaterials based on charge, size, surface functionalization, targeting, and cell-type,
there are ample opportunities to further advance treatment for translation into the clinic. Further
advancements in the field of biomaterials for cancer immunotherapy will depend on expertise
across several disciplines such as immunology, nanomedicine, and material science.
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Chapter 2: Bispecific T cell Engagers for the
Treatment of Multiple Myeloma: Achievements and
Challenges.
2.1 Introduction
MM is a neoplastic plasma cell dyscrasia that primarily arises in the bone marrow, the second
most common hematological malignancy, and represents approximately 20% of deaths from
hematopoietic cancers [180]. Mainstay therapies for MM, such as corticosteroids, proteasome
inhibitors, and immunomodulatory drugs, have shown significant clinical success and improved
patient survival [181]. With the never-ending improvements of standard-of-care practices in
MM, the current median survival has recently surpassed six years [182, 183]. However, MM is
notoriously incurable and patients who fall victim to this disease eventually relapse. Therefore,
novel therapeutic strategies used as a monotherapy or in combination with standard-of-care
treatment regimens are highly warranted to improve the therapeutic landscape in MM.
T cell-based immunotherapy is solidifying itself as a major pillar for the treatment of
MM. The concept of targeting T cells during the early stages of immunotherapy development
was conceived following the observation of the T cell’s ability to eliminate blood cancers and
harm normal tissue via graft-versus-leukemia and graft-versus-host disease, respectively [184].
This has led to extensive research in immunotherapies focused exclusively on T cells and ways
to hone T cell-directed cytotoxicity on cancer cells while mitigating potential deleterious effects.
Examples of T cell-based immunotherapy used for MM include immune checkpoint inhibitors,
CAR-T cells, and BTCEs [185-187]. In this review, we provide a brief overview of BTCEs being
investigated in the clinic currently for the treatment of MM and address the general achievements
and challenges of this emerging immunotherapy option.
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2.2 Bispecific T cell Engagers
2.2.1 Mechanism of Action
All BTCEs are a class of bispecific antibodies that are made up of two scFvs which are
connected by a protein linker [188] as shown in Figure 1. These scFvs bind to MM and T cells
by targeting the desired MM antigen and the CD3 subunit of the TCR, respectively. The first
bispecific antibody that was produced and published on was in 1972, and strategies for
improving BTCE antibody manufacture are always ongoing [189-191]. Once the BTCE is bound
to the target antigen and CD3, this subsequently leads to formation of a cytolytic synapse,
upregulation of T cell activation and granule expression, and polyclonal expansion of the T cells
[192-194]. BTCE-induced T cell activation is 1) extremely potent; 2) highly specific; 3)
independent of TCR specificity; 4) does not need co-stimulation of CD28 and/or other costimulatory molecules; and 5) does not require peptide antigen presentation for target cell lysis.
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Figure 1. Creation of the Bispecific T cell Engager. The anti-TAA scFv specifically recognizes the
desired TAA on the tumor cell while the anti-CD3 scFv recognizes the CD3 molecule on the T cell. This
enables a highly specific and bivalent system for T cell-based immunotherapy.

The activation of T cells is only triggered upon concomitant binding of the TCR and
target cell to the BTCE. BTCEs do not activate T cells by solely binding to the TCR due to their
low affinity [195]. The general basis of how a BTCE activates a T cell is explained by the
kinetic-segregation model [196] (Figure 2). CD45 is a transmembrane protein, constituted of a
large extracellular domain and an intracellular phosphatase, the phosphatase domain of CD45
interacts with the TCR and dephosphorylates it, and hence prevent its activation [197, 198]. In a
resting T cell, the net phosphorylation of the TCR is kept at a minimum due to
dephosphorylation by CD45 [196], as shown in Figure 2A. Physiologically, when the T cell
interacts with an APC, the TCR binds to the MHC with the antigen it is presenting, forming a
close-contact zone immune-synapse. The close proximity of the T cells to the APC push away
the extracellular domain of CD45, due to its large size (∼30-50 nm) [199], which prevents the
CD45 from interacting an dephosphorylating the TCR, and allows the activation of the T cell
[200] (Figure 2B). BTCE-directed lytic synapses formed between T cells and target cells
closely mimic those formed naturally through the TCR and MHC class peptide antigen
interactions [201]; this is done by initiating an interaction between the T cell and target cell
directly through cell specific antigens induced by the BTCE, as shown in Figure 2C. Once the
BTCE is bound to the target antigen on the cancer cell and CD3 on T cells, the BTCE-induces
formation of a close-contact zone immune-synapse that pushes the extracellular domain of CD45
away from the TCR, preventing its dephosphorylation and subsequently allowing T cell
activation. The distance between the T cell and the other cells in the close-contact zones in the
immune-synapse can be up to 300 nm for sufficient TCR stimulation [202]; nonetheless, smaller
contact zones and size of target antigen leads to better activation and efficacy of BTCE [203].
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Figure 2. Molecular mechanism of BTCE-induced T cell activation. A) The kinetic-segregation model
proposes that the exclusion of CD45 is a prerequisite for T cell activation. B) As the APC gets in
proximity of the T cell, CD45 is subsequently excluded, and the peptide major histocompatibility
complex (pMHC) interacts with the TCR and enables activation. C) For BTCE-induced T cell activation,
the BTCE brings the tumor cell in proximity of the T cell to exclude CD45 from the close-contact zone
and enable subsequent T cell activation.

2.2.2 Advantages
2.2.2.1

High Potency and Efficacy

BTCEs prove highly promising as a therapy due to their high potency and efficacy. The high
potency of BTCEs is reflected by the low concentrations (picomolar range or lower) and low
effector: target ratios required to demonstrate significant, specific lysis of target cells [192, 193,
201, 204]. In the presence of BTCEs, serial lysis of tumor cells by T cells has been
demonstrated, allowing for a robust response, and increasing the efficacy and potency of BTCEs
[205]. BTCEs are able to stimulate the production of lytic synapses without the normal
TCR/MHC antigen recognition mechanism [194, 206]. The small size of the BTCEs
(approximately 55 kDa and 11 nm in length) brings the T cell and target cell into close proximity
necessary to form a synapse [207]. This mechanism explains the high efficacy of BTCEs, as they

31

are able to overcome tumor immunosuppressive mechanisms to evade the immune system, such
as downregulation of MHC antigen presentation and molecules for co-stimulation [194, 207].

2.2.2.2

Safety

In addition to their efficacy, BTCEs demonstrate suitable safety. BTCEs have demonstrated high
selectivity for target antigens, with no signs of T cell activation in the absence of a target antigen
[208]. Unlike CAR-T cells which are already activated ex vivo, with BTCEs, T cells only
become activated when a target cell is also present and bound to the BTCE, minimizing
potentially harmful cytokine secretion in the absence of the target tumor cell [188, 209]. In a
phase I clinical trial of the Amgen’s BCMA/CD3 BTCE (NCT03836053) in relapsed and/or
refractory MM patients, AMG 420 demonstrated rates of cytokine release syndrome lower than
those found for CAR-T cells that are directed to the same target [187].

2.2.2.3

Availability off-the-shelf

As a therapeutic, BTCEs are available in an “off-the-shelf” manner, ready for immediate
treatment use [206, 210]. The act through the activation of endogenous T cells, and unlike CART cells, no ex vivo manipulation of patient immune cells is necessary in order to achieve a direct
interaction between T cells and target cells [205]. This decreases the need to determine patient
tumor-specific antigens for manipulation of T cells ex vivo, which is particularly beneficial as
some tumors may not have distinctive antigens for targeting [204, 211].

2.2.2.4

Lower Cost

Currently, a typical drug treatment regimen such as a combination of bortezomib and
dexamethasone costs around $125,000 per MM patient [212]. The FDA-approved BTCE for BALL, blinatumomab, sells for around $89,000 per course of therapy [213]; whereas, CAR-T cells
carry a higher financial burden for MM patients with a cost of around $500,000 per treatment
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[214]. The low cost of producing BTCEs stems from the advanced technologies that are
currently available for the production of antibodies. This might lead to further developments in
perfecting the state-of-the-art techniques used for the assembly of BTCEs and hence decreasing
the overall price of using BTCEs for MM treatment.

2.2.3 Challenges
2.2.3.1

Poor Pharmacokinetic Profile

The small size of the traditional BTCE (approximately 55 kDa and 11 nm in length) confers its
poor absorption, distribution, metabolism, and excretion properties [188]. Similar to other small
proteins, the traditional BTCE is also systemically eliminated via nonspecific catabolism;
whereas, monoclonal antibodies (~150 kDa) have prolonged distribution in the blood due to
neonatal Fc receptor (FcRn)-regulated protection of the Fc receptor [215, 216]. Blinatumomab
and other BTCEs of the same format have a typical half-life of around 2 hours; due to the very
short half-life, BTCEs have to be continuously administered intravenously for a cycle of 28 days
[217]. Circumventing the poor pharmacokinetic profile of the traditional BTCE is one of the
main reasons that more efforts are transitioning to investigating BTCEs that contain an Fc
receptor.
Methods to circumvent the poor pharmacokinetic profile of BTCEs include
supplementing an Fc region onto the BTCE structure. AMG 701 is an example of this; Amgen
included an Fc region onto the scFvs to be able to take advantage of the FcRn-regulated
protection of the BTCE [215, 216]. Another example of prolonging the pharmacokinetic profile
of the BTCE is including a single chain domain antibody that binds to albumin. This also takes
advantage of the FcRn-mediated serum half-life extension. Harpoon Therapeutics use the anti-
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albumin technology to extend the half-life of their BTCE by non-covalently binding to albumin
which avoids low affinity Fc receptor binding [218].

2.2.3.2

Laborious and Cumbersome to Produce

Generally, creating a particular monoclonal or bispecific antibody takes about six months [219];
this is due to the long and laborious process that is required to successfully create the BTCE of
interest. The standard operating procedure for making a BTCE is first started by creating the
desired DNA constructs using gene synthesis [191]. Phage display is used to develop the
sequences of human variable fragments [220]. Once the preferred gene is isolated, assembled,
and sequenced, restriction enzymes are introduced at both ends of the scFv gene to induce
ligation of the gene and plasmid for subsequent cloning and plasmid construction [221]. The
above process is repeated once more for the creation of the second scFv. Both scFvs are linked
together using a short peptide that contain glycine and serine which are most commonly used for
linkers [222]; this method is done by polymerase chain reaction. The resulting product is
expressed in a bacterial or mammalian system such as Escherichia coli or Chinese hamster ovary
cells, respectively, to achieve larger quantities of the BTCE [223, 224]. Following propagation,
the BTCE is reduced and refolded to create active molecules. Then the final product is achieved
by purification via ion-exchange chromatography. Protein concentration and purity is finally
assessed using Bradford assay and sodium dodecyl sulfate–polyacrylamide gel electrophoresis,
respectively [221, 224]. Techniques entailing the process of fusing Fc regions to BTCEs adds
another dimension of complexity and is described in more detail elsewhere [220].

2.2.3.3

Inability to Target Multiple Antigens

Cancer is a multi-clonal disease; each clone can express different patterns of tumor antigens.
Within the same patients the existence of several clones that may express different levels (or no
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levels) of tumor antigens expressed on the dominant clone was observed [225], which may
significantly limit the efficacy of BTCEs targets one tumor antigen only. To further explain this
phenomenon, we demonstrated the concept schematically in Figure 3. Assuming a multi-clonal
tumor with three different each has high expression of different surface antigens A, B or C, with
the clone expressing antigen A as the dominant clone. The estimative approach to treat this
tumor would be an anti-antigen A BTCE, which may indeed eradicate the clone with high
expression of antigen A but leaving behind the other two clones B and C, which are antigen-less
of A, to escape the treatment, proliferate and induce relapse of the disease. In addition, antigen
loss or downregulation of specific surface antigens is a common mechanism observed in cancer
cells treated with targeted therapy against the specific antigen [226]. For instance, patient treated
with BCMA-targeted CAR-T cells, BCMA expression on MM cells was decreased significantly
[227], which raises the need to create BTCEs with the ability to target multiple tumor antigens
simultaniously to circumvent antigen-less tumor escape and patient relapse.

Progression of
clones B and C
(lacking antigen A)

Treatment with
BTCE against
tumor antigen A

Heterogeneous multi-clonal
Primary tumor
(majority of clone A)

Eradication of clone A,
Tumor escape of antigenless clones B and C

Relapse of disease
due to clones B and C

Figure 3. Schematic of the mechanism of tumor escape after treatment. Immunotherapies targeting
one antigen due to development of antigen-less tumor clones which cause relapse of the disease.

In addition to the incapability of targeting more than one surface antigen on the cancer
cell, there is also a need to target additional antigens on the T cell, other than CD3. Targeting
CD28, in addition to CD3, as co-stimulatory receptor was shown to significantly induce more
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profound and sustained activation and proliferation of T cells [228]. In CAR-T cells, persistence
and antitumor lysis was significantly augmented when co-stimulatory molecules such as ICOS
and 4-1BB were incorporated in the CAR [229]; therefore, BTCEs also are in need of the ability
to target co-stimulatory receptors to prevent exhaustion and increase the antitumor effects of T
cells.
The development of TCEs that target multiple antigens is challenging due to the highly
sophisticated nature of producing TCEs. Nabel and colleagues recently created a trispecific
TCEs targeting CD38, CD3, and CD28 for the treatment of MM [230]. They investigated the
levels of cytokine secretions, T cell activation, and T cell-redirected MM lysis in vitro and in
vivo induced by the trispecific TCE. However, several concerns remain following the production
of the first trispecific TCE for MM such as safety and feasibility to be able to progress towards
the potential of creating a more multivalent TCE for MM.
In addition, Harpoon Therapeutics are currently investigating a trispecific TCE targeting
T cells, MM, and albumin using anti-CD3, anti-BCMA, and anti-albumin, respectively. As
mentioned before, the rationale for including anti-albumin is to substantially increase half-life.
This creates a trispecific TCE that is only ~50 kDa which is a third of the size of a monoclonal
antibody [218].

2.3 BTCEs for the Treatment of MM
The central tenet of making an efficacious BTCE is to be able to target the malignant cancer cells
without harming normal tissue to reduce off-target toxicities. The optimal antigen target would
have high and universal expression on the cancer cells but not on other normal cells [225]. MM
tumors are multi-clonal, highly heterogeneous, and genetically unstable [231-233]. Due to the
high mutational burden of MM and the multi-clonal nature of the tumors, selecting a single most
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preferred target is oftentimes challenging. We have listed below a list of the most pursued
antigen targets for the treatment of MM using BTCEs.

2.3.1 BCMA
All BCMA, B cell maturation antigen also known as CD269 and TNFRS17, mediates the
survival and growth of B cells and plays a critical role in the maturation and differentiation of B
cells to plasma cells [234]. Persistence and long-term survival of plasma cells are hindered when
BCMA expression is knocked out of plasma cells [235]. Most importantly, malignant plasma
cells express significantly higher levels of BCMA compared to their normal counterparts which
validates BCMA as a selective immunotherapeutic target for MM. There is a direct relationship
of the overexpression and activation of BCMA as MM progresses [236]. BCMA is used a
biomarker for MM due to its significant high expression. In addition, BCMA is universally and
preferentially expressed on plasma cells with little to no expression in other hematologic cells.
The only exception is plasmacytoid dendritic cells which have been shown to help survival of
MM in the bone marrow [237].
Amgen created a BCMA/CD3 BTCE called BI 836909 and investigated the effect of
their product in the preclinical setting [208]. BI 836909 is a BTCE with a BCMA and CD3 scFv
connected by a protein linker. The hallmarks of T cell activation and cytolytic activity in MM
cell lines and primary patient samples were observed. Xenograft tumors and plasma cells in vivo
and in cynomolgus monkeys, respectively, were eradicated by BI 836909. BI 836909 was later
named AMG 420, and Amgen have an active trial to assess the maximum tolerated dose (MTD)
of AMG 420 in patients with relapsed and/or refractory MM (NCT03836053; Table 1). The
maximum dose tested was 800 μg/day of continuous intravenous administration for four weeks
which led to grade 3 adverse events; 400 μg/day was found to be the MTD for this study [238].
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Serious adverse events were seen in half of the patient cohort which consisted of peripheral
neuropathy and infections. Secondary outcomes included a response rate of 70% at the MTD and
an overall response rate of 31%.
Table 1. BTCE Clinical Trials in MM
Clinical Trial
Number

Phase

Status

BiTE name

BiTE Target

Completion
Date

NCT03173430

I

Terminated

Blinatumomab

CD19

2019

NCT03445663

I/II

Recruiting

AMG 424

CD38

2022

NCT03309111

I/II

Recruiting

GBR 1342

CD38

2021

NCT03275103

I

Recruiting

BFCR4350A

FcRH5

2021

NCT02514239/
NCT03836053

I

Active/
Recruiting

AMG 420

BCMA

2020/
2025

NCT03287908

I/II

Recruiting

AMG 701

BCMA

2025

NCT03761108

I/II

Recruiting

REGN5458

BCMA

2022

NCT03933735

I

Recruiting

TNB-383B

BCMA

2021

Another Amgen BTCE that is targeted to BCMA is AMG 701. The difference between
Amgen’s two BTCEs is that AMG 701 has an extra Fc region to extend half-life. AMG 701 has
been demonstrated to induce potent and specific MM cell lysis in vitro and in vivo [239]. In
Amgen’s study, they found that the elimination half-life of AMG 701 is around 112 hours in
cynomolgus monkeys. This study has prompted initiation of phase I/II clinical study to
investigate the pharmacokinetic, pharmacodynamics, and efficacy of AMG 701 (NCT03287908).
An additional BCMA/CD3 BTCE, REGN5458, is currently being investigated by Regeneron
Pharmaceuticals [240]. Structurally, REGN5458 contains an Fc region with BCMA Fab and
CD3 Fab domains. Preclinical data conclude that REGN5458 induced T cell-mediated lysis of
MM cell lines and primary plasma cells in vitro. Additionally, xenograft tumors were eliminated
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when dosed at 4 mg/kg intravenously for twice a week. A phase I/II clinical trial was
subsequently initiated to investigate the dose-limiting toxicities of REGN5458 (NCT03761108;
Table 1). All patients included in the clinical study exhibited MM progression after undergoing
three or more prior lines of treatment. Two (50%) patients were minimal residual disease
negative following a weekly administration of 6 mg of REGN5458, and five (71%) patients had
treatment-emergent adverse events related to the study (NCT03761108).
TeneoBio has also created a BCMA BTCE called TNB-383B that eliminates MM cells in
vitro and in mice with minimal toxicity [210]. TeneoBio have shown that the TNB-383B has
significantly lower cytokine release with sufficient anti-tumor efficacy compared to other BTCEs
targeting BCMA. An advantage of TNB-383B is the use of fully human scFvs in the BTCE
structure to avoid any unwanted immune response that can come from using mouse scFvs.
Teneobio has teamed up with AbbVie to conduct a clinical trial using TNB-383B to investigate
the MTD and pharmacokinetic profile of the BTCE in patients with relapsed or refractory MM
(NCT03933735; Table 1).
Harpoon Therapeutics have created a novel trispecific TCE (HPN217) that targets T
cells, MM, and albumin using anti-CD3, anti-BCMA, and anti-albumin, respectively. HPN217
has been shown to induce cytotoxicity in vitro and has demonstrated greater potent killing of
MM cells with higher number of BCMA receptors per cell [241]. Harpoon has also shown CD69
and CD25 upregulation and cytokine secretion which are all hallmark markers of T cell
activation. MM cell lysis and pharmacokinetic profiles were shown in mice and cynomolgus
monkeys, respectively. The extended half-life of HPN217 was around 85 hours, whereas the
normal BTCE half-life is around 2 hours [217].
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2.3.2 CD38
The CD38 receptor is a transmembrane glycoprotein that acts as an adhesion molecule and
mediator for cell growth and calcium signaling for MM [242]. CD38 is highly expressed on the
vast majority of MM cells, however it is also expressed (to lower extent) on various
hematopoietic cells, including monocytes, B cells, T cells, and natural killer cells [243, 244].
CD38 has served as a target for the treatment of MM for multiple treatment regimens and have
shown promising results in the clinic for monoclonal antibodies, such as daratumumab,
isatuximab, and MOR202 [245, 246], and CAR-T cells (NCT03464916); thus, validating CD38
as a therapeutic target for MM.
Amgen’s CD38/CD3 BTCE has been investigated in the preclinical setting (AMG 424)
[247], and Amgen is currently recruiting patients to begin a phase I/II clinical trial
(NCT03445663; Table 1). AMG 424 deviates from the traditional BTCE structure that consists
of only scFv fragments. An Fc region supports the base of AMG 424 with a CD38 fragment
antigen binding (Fab) domain on one side and CD3 scFv on the other. AMG 424 induced MM
cell killing in vitro and in vivo and depleted the targeted B cells in cynomolgus monkeys; B cells
were the primary outcome in this study due to the technically challenging nature of tracking
plasma cells in cynomolgus monkeys. However due to the ubiquitous expression of CD38 on
normal tissue, the potential toxicities of AMG 424 were also assessed in the mentioned study.
The authors concluded that the depletion of monocytes and T cells only occurred at significantly
large doses (EC50 of 42 and 325 pmol/L, respectively) compared to the depletion of B cells
which only had an EC50 of 8 pmol/L in peripheral blood mononuclear cells of cynomolgus
monkeys [247]. This preclinical study has led to the initiation of a phase I/II clinical trial for the
treatment of patients with relapsed and/or refractory MM (NCT03287908).
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Another CD38/CD3 BTCE has been pushed to a phase I/II clinical trial by Ichnos
Sciences (NCT03309111; GBR 1342; Table 1). According to Ichnos Sciences, the investigators
delineate the structure of GBR 1342 to be very similar to that of AMG 424 [248]. The structure
of GBR 1342 includes a Fc region with a CD38 scFv and CD3 Fab domain, whereas Amgen
created AMG 424 with a CD38 Fab domain and CD3 scFv. GBR 1342 was shown to induce
antitumor activity in vitro. The authors also monitored the depletion of T cells and monocytes in
cynomolgus monkeys. They found that GBR 1342 depleted T cells and CD38-positive
monocytes and observed a rebound of both cell types after approximately 48 hours [249].
There is also a trispecific TCE targeting MM, co-stimulatory molecule of the T cell, and
the TCR by using anti-CD38, anti-CD28, and anti-CD3. The rationale for targeting CD28 is to
enable enhanced and persistent T cell activation. The trispecific TCE enables cytolysis of MM
and activation of T cells in vitro and in vivo. Additionally, Nabel’s group investigated the TCE
in primates and found that the MTD varied based on administration. Intravenous administration
showed an MTD of 30-75 ug/kg whereas for subcutaneous, MTD was greater than 100 ug/kg;
this is most likely due to the greater serum antibody levels in the blood following intravenous
injection.

2.3.3 FcRH5
FcRH5, also known as CD307, FcRL5, and IRTA2, is an immunoregulatory cell surface
molecule that is expressed only on B cells and remains on their surface as they mature to plasma
cells, unlike major B-cell markers such as CD19, CD20, and CD22, which are lost in plasma
cells [250]. As an immunotherapeutic target, FcRH5 is highly attractive due to its consistent
expression on different developmental stages of B cells and the ability to utilize FcRH5 as a
general target for other B cell malignancies [251, 252]. FcRH5 are always expressed on plasma
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cells, whereas other specific mature B cell markers are downregulated [250]. FcRH5 mRNA is
additionally overexpressed in MM compared to other hematopoietic cells. FcRH5 is a universal
and novel target and is being pursued for treatment regimens such as CAR-T cells [253].
Genentech created a BTCE with two Fab domains (one targeting FcRH5 and the other
targeting CD3) and an Fc portion at the base of the bispecific IgG [254]. The proof-of-concept of
Genentech’s FcRH5/CD3 BTCE has been extensively investigated in vitro, in vivo, and in
cynomolgus monkeys [203, 254]. Preclinically, the FcRH5/CD3 BTCE induced T cell activation
in vitro concurring with the kinetic-segregation model, and the authors investigated the ability of
the BTCE to induce T cell activation and killing as the targeted epitope location is distal, central,
or proximal to the cell membrane [203]; they found that the membrane-proximal epitope
produced a more efficient T cell synapse and enhanced killing of MM. Li et al. also exhibited the
ability of the FcRH5/CD3 BTCE to redirect T cells to lyse MM patient samples, a MM cell line,
and plasma cells in vitro, in vivo, and in cynomolgus monkeys respectively [203]. In addition,
Genentech recently optimized their FcRH5/CD3 BTCE to enable negligible antibody-dependent
cell-mediated cytoxicity and investigated whether or not this would impair its ability to induce T
cell activation and T cell-redirected MM cell lysis [254]. This BTCE will be translated to a phase
I clinical trial to primarily determine the adverse events that occur during and after
administration of the FcRH5/CD3 BTCE in MM patients (NCT03275103; Table 1).

2.3.4 CD19
CD19 is a cell surface marker that acts as a coreceptor in antigen receptor-mediated activation of
B cells and enhances intracellular signaling [255]. Normal plasma cells express CD19, whereas
generally CD19 is not present on the surface of MM [256]. CD19 has been only shown to be
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expressed on MM in rare occasions [257]. However, a certain population of MM expresses very
low levels of CD19 and is known to have an aggressive stem-like phenotype [256, 258].
Blinatumomab, a CD19/CD3 BTCE, has been approved for the treatment of B-cell acute
lymphoblastic leukemia (B-ALL) [259, 260]. Blinatumomab has been proposed to target this
aggressive subset of MM. Yet, there are currently no published studies that investigate
blinatumomab for MM preclinically, and the only clinical trial that is studying the feasibility and
safety of blinatumomab for the treatment of MM has been terminated recently (NCT03173430;
Table 1).

2.3.5 CD138
CD138 or syndecan-1 is a canonical cell marker that is highly expressed and very abundant on
MM and plasma cells. CD138 has been shown to increase tumor progression and survival and
induces angiogenesis, cytoskeletal formation, adhesion, and signaling [261]. It has also been
shown to interact with cytokines, chemokines, and growth factors to exert molecular roles in
tumorigenesis. The gold standard marker to detect MM is the use of CD138 due to the very high
presence of the marker on MM [232]; however, CD138 can be shed which can regulate function
and stability [262]. CD138 is universally expressed on MM cells; however, different
perturbations to MM cells can decrease expression such as hypoxia which could be the reason
for failure of many CD138-targeted therapies [263].
A CD138 BTCE has been made to combat MM cells with the targeted surface marker.
This specific BTCE actually includes an Fc portion to engage natural killer cells as well as T
cells[264]. This particular aspect of including an Fc region enables increased half-life (which
was not shown in this study [264]) and engagement of natural killer cells to induce an even
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greater immune response against MM. They found that the BTCE bound to natural killer, T cells,
and MM cells to form a complex that induced MM cell killing. The CD138 BTCE was able to
upregulate CD69 and CD25 expression and activate CD4 and CD8 T cells. T cell-mediated MM
cell lysis was observed using fluorescent microscopy and was able to induce anti-tumor efficacy
in vitro and in vivo.

2.3.6 Novel TCE Strategies
CD138 Recently, our group has shown that nanoparticles, particularly liposomes, can be used as
a surrogate to bispecific antibodies for the engagement of T cells [265]. We have shown
previously that our nanoparticle T cell engager (nanoTCE) was able to circumvent the
disadvantages of the traditional BTCE mentioned in this review including poor pharmacokinetic
profile, laborious and cumbersome to produce, and inability to target multiple antigens. Our
nanoTCE is able to reach 60 hours in blood serum in vivo; can be made simply, reproducibly,
and quickly; and customized to target any desired antigen of interest inside or outside the realm
of MM [265].
The nanoTCE concept was proven using CD20 as a target for lymphoma. The CD20
nanoTCE was able to induce cancer cell lysis and T cell activation by upregulating CD69
expression in vitro and in vivo [265]. As mentioned previously, MM is highly heterogeneous and
targeting one marker creates antigen-less tumors and creates relapse for the MM patient (Figure
3). Therefore, we sought to create a nanoparticle multispecific T cell engager (nanoMuTE) to
target more than one MM surface marker and reduce any potential creation of antigen-less
clones. We targeted three very abundant markers on MM: BCMA, CS1, and CD38 [266]. Each
of these markers are individually present on MM cells; however, expression differs from patient
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to patient [265]. This creates a sound rationale for the targeting of multiple cancer antigens
which is currently impossible for traditional TCEs.
We have shown that each nanoTCE targeting CD3 and BCMA, CS1, or CD38 induced T
cell activation (upregulation of CD69) and cytokine secretions (IL-2, IL-6, IL-10, TNF-α, and
IFN-γ), while nanoMuTEs, which target all three MM markers and CD3, enabled even greater T
cell activation compared to each individual nanoTCE [265]. The same trend was also seen with T
cell-mediated MM cell lysis in vitro and in vivo, where nanoMuTEs induced greater MM
cytolysis than each nanoTCE. Furthermore, we portray two different models of antigen-less
tumor escape. We demonstrated that using single-targeted nanoTCEs induced antigen-less tumor
escape due to the elimination of MM cells only expressing one single marker; whereas,
nanoMuTEs eliminated all MM cells with BCMA, CS1, and/or CD38 expressed and did not
create any antigen-less MM clones [265]. Nanomaterials used for TCEs for other cancers such as
breast cancer is described elsewhere [267].

2.4 Conclusions
The development of TCEs for the treatment of MM is rapidly growing. There have been many
findings regarding the activation of T cells and elimination of MM in vitro and in vivo; with
many pharmacokinetic analyses in primates [268]. High potency and efficacy, safety, availability
off-the-shelf, and low cost are all current advantages of TCEs. These traits allow TCEs to be
very attractive as an immunotherapy for MM compared to CAR-T cell therapy. However, TCEs
are not perfect and have many disadvantages associated. Disadvantages include poor
pharmacokinetic profile, laborious and cumbersome to produce, and inability to target multiple
antigens. The goal of creating a TCE that circumvents all current disadvantages while using
antibody technology is still underway. Using nanomaterials to circumvent current TCE
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limitations have significant potential to advance TCE immunotherapy and be beneficial for the
treatment of MM and patients in the near future.
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Chapter 3: Nanoparticle T cell Engagers as a Modular
Platform for Cancer Immunotherapy
3.1 Introduction
Cancer immunotherapy improves the ability of the immune system to recognize and combat
cancer cells, which enables long-term remission in cancer patients and is also in the forefronts of
cancer therapy [214, 269]. T cell-based immunotherapies include CAR-T cells and BTCEs.
CAR-T cells are autologous T cells obtained from individual patients and are genetically
engineered to express an antibody scFv to recognize and kill cancer [270]. BTCEs are tandem
scFv fragments connected by flexible linkers with one scFv targeting a T cell specific molecule
such as CD3, while the other targets a tumor-associated antigen, which allows the BTCEs to
redirect the T cell to the cancer cell, leading to T cell-redirected activation and tumor killing
[188, 193, 271, 272].
T cell-based immunotherapy has shown promising clinical outcomes in many cancers
including MM [271, 272] and Waldenstrom Macroglobulinemia (WM) [273]; however, these
have significant limitations. CAR-T cells must be extracted from the patient, activated,
expanded, genetically engineered, and purified ex vivo for reinjection into the patient [274, 275].
This process imposes technical challenges and significant expense [110]. BTCEs, on the other
hand, have the advantage of being off-the-shelf for immediate use in patients [276]; however,
they have a poor pharmacokinetic profile, with a half-life of around two hours [277], imposing
compromised patient quality of life, and increased risk of infections-related deaths [62, 278-280].
Therefore, there is an urgent need to develop new forms of T cell immunotherapies that
overcome these limitations.
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3.2 Methods
3.2.1 Materials and Reagents
All biotinylated and fluorescent antibodies, human CD138 microbeads, and Pan T Cell Isolation
Kits were purchased from Miltenyi Biotec (Bergisch Gladbach, Germany). DMEM, RPMI-1640,
L-glutamine, penicillin-streptomycin, and phosphate buffered saline (PBS) were purchased from
Corning (Corning, NY). Fetal bovine serum, live-cell dyes, lipophilic tracers, collagenase, and
counting beads were purchased from Life Technologies (Carlsbad, CA). 1,2-dipalmitoyl-snglycero-3-phosphocholine (DPPC), 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N[amino(polyethylene glycol)-2000] (DSPE-PEG2000), and polycarbonate membranes were
purchased from Avanti Polar Lipids (Alabaster, AL). Cholesterol and chloroform were
purchased from Millipore Sigma (Burlington, MA). Streptavidin conjugation kit was purchased
from Abcam (Cambridge, United Kingdom). Human Cytokine Array Q1 was purchased from
Raybiotech (Peachtree Corners, GA). All mice used in this study were NCG (strain: 572),
female, 50-56 days old, and purchased from Charles River (Wilmington, MA). All mice
experiments in this study were in compliance with the Institutional Animal Care and Use
Committee at Washington University.

3.2.2 Cells
H929, MM.1S, and RPMI-8226 were purchased and authenticated by American Type Culture
Collection (ATCC; Manassas, Virginia). All cell lines were tested for mycoplasma
contamination. BCWM.1 and MWCL.1 were a gift from Irene Ghobrial. Primary bone marrow
samples were isolated from MM patients at Washington University School of Medicine (IRB #
201102270) and subsequently selected for MM cells with the use of CD138 human microbeads.
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Informed consent was obtained from all individuals in accordance with the Declaration of
Helsinki. Normal donor peripheral blood mononuclear cells (PBMCs) were isolated from healthy
donors using Ficoll centrifugation [281] and subsequently separated for T cells using a human
Pan T cell isolation kit (Miltenyi Biotec). Hs505.T cells were cultured in DMEM with 4.5 g/L
glucose and L-glutamine with the addition of addition of 10% fetal bovine serum and 1%
penicillin-streptomycin. The other cell lines were cultured in RPMI-1640 with the addition of
10% fetal bovine serum, 2 mM of L-glutamine, and 1% penicillin-streptomycin.

3.2.3 Preparation and Characterization of the nanoTCEs and
nanoMuTEs
Nanoparticle T cell engagers (nanoTCEs) consisted of three components: cholesterol, DPPC, and
DSPE-PEG2000 with a mass ratio equivalent to 30: 65: 5, respectively. Lipids were mixed and
solubilized in chloroform and evaporated to form a thin film [282, 283]. Then, the film was
hydrated with PBS, and the resulting suspension was extruded using the Avestin LiposoFast LF50 (Ottawa, Ontario, Canada) with 100 nm polycarbonate membranes to yield unilamellar
liposomes. Streptavidin was conjugated to the amine groups on the surface of the liposomes
according to the protocol of the manufacturer (Abcam), to activate the liposomes. Biotinylated
antibodies were added to bind to the streptavidin for targeting, as previously described [284]. For
detailed amounts of each reagent used, please see Table 2. Malvern Zetasizer Nano ZS90
(Malvern, Worcestershire, United Kingdom) was used to determine zeta-potential, diameter, and
polydispersity index of each preparation (see Table 3 for details).
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Table 2. Amounts of Lipids and Antibodies Used to Make Each Liposome Formulation

130111336
0.150
µL

130104500
0.110
µL

13

3.2

3.8

0.1

BCMA Liposomes (1 ab/liposome)

13

3.2

3.8

0.1

199

BCMA Liposomes (3 ab/liposome)

13

3.2

3.8

0.1

597

BCMA Liposomes (10 ab/liposome)

13

3.2

3.8

0.1

1990

CS1 Liposomes (1 ab/liposome)
CS1 Liposomes (3 ab/liposome)
CS1 Liposomes (10 ab/liposome)
CD38 Liposomes (1 ab/liposome)
CD38 Liposomes (3 ab/liposome)

13
13
13
13
13

3.2
3.2
3.2
3.2
3.2

3.8
3.8
3.8
3.8
3.8

0.1
0.1
0.1
0.1
0.1

CD38 Liposomes (10 ab/liposome)

13

3.2

3.8

0.1

Isotype/CD3 nanoTCEs
CD20/CD3 nanoTCEs
BCMA/CD3 nanoTCEs
CS1/CD3 nanoTCEs
CD38/CD3 nanoTCEs

13
13
13
13
13

3.2
3.2
3.2
3.2
3.2

3.8
3.8
3.8
3.8
3.8

0.1
0.1
0.1
0.1
0.1

874
874
874
874
874

BCMA/CS1/CD38/CD3 nanoMuTEs

13

3.2

3.8

0.1

874

CD20/CD3 nanoTCEs (no PEG)

13

3.2

0.1

874
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130- 130099- 113575 430
0.044 0.022
µL
µL

146
438

CD20 Liposomes (10 ab/liposome)

1.1

CD38

BCMA

130113448
0.020
µL

CS1

CD20

130Cat # 850355 C8667 880128 860376 ab102921 113137
Concentration (mg/mL)
0.022
Unit
mg
mg
mg
mg
mg
µL
Pegylated Liposomes
13
3.2
3.8
0.1
CD3 Liposomes (1 ab/liposome)
13
3.2
3.8
0.1
874
CD3 Liposomes (3 ab/liposome)
13
3.2
3.8
0.1
2622
CD3 Liposomes (10 ab/liposome)
13
3.2
3.8
0.1
8740
CD20 Liposomes (1 ab/liposome)
13
3.2
3.8
0.1
CD20 Liposomes (3 ab/liposome)
13
3.2
3.8
0.1

Isotype

CD3

Streptavidin

18:0 PC-EtNH2

Biotinylated Antibodies

DSPE-PEGNH2

Cholesterol

DPPC

Lipids

1460

497
1491
4970
994
2982
9940
1092
146
199
497
994
199
146

497

994

Table 3. Parameters for each nanoTCE or nanoMuTE.

Formulation

Mean Size (nm)

Polydispersity Index

Zeta Potential (mV)

Isotype/CD3

127.9 ± 3.6

0.066 ± 0.030

0.67 ± 0.32

CD20/CD3

128.1 ± 11.3

0.085 ± 0.034

1.41 ± 0.70

BCMA/CD3

133.2 ± 9.3

0.091 ± 0.017

-0.02 ± 0.05

CS1/CD3

123.4 ± 8.4

0.082 ± 0.040

0.61 ± 0.50

CD38/CD3

125.4 ± 8.3

0.107 ± 0.006

0.39 ± 0.38

BCMA/CS1/CD38/CD3

125.2 ± 0.5

0.047 ± 0.021

0.84 ± 0.34

3.2.4 Pharmacokinetics of nanoTCEs and nanoMuTEs
Each nanoTCE or nanoMuTE was stained with a fluorescent tracer (DiD and injected IV
injection to NSG mice at .5 mg/mouse (n=3 for each formulation). Blood (50

l) was taken

from the tail vein of each mouse before treatment, and 0.25, 6, 24, 48, 72, and 96 hours after
treatment. Fluorescence of whole blood or plasma was measured at 644/665 nm using a
SpectraMax i3 plate reader (Molecular Devices, San Jose, CA). Half-life was calculated using
polynomial regression.

3.2.5 Cell Surface Protein Expression Analysis
Cell lines or primary CD138+ MM cells were incubated with APC-anti-CD20, APC-antiBCMA, APC-anti-CS1, or APC-anti-CD38 antibodies in 4°C for one hour; then washed, spun
down, resuspended in 100 l and analyzed by flow cytometry using MACSQuant Analyzer 10
with Ex= 635nm and Em= 655-730 nm [285]. Cells were gated using FSC and SSC, and
analyzed for relative mean fluorescent intensity (RMFI) of APC using BD FlowJo Software
[286].
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3.2.6 Liposome Binding and Binding Following Antigen Loss In
Vitro
Each nanoTCE or nanoMuTE was stained with a fluorescent tracer DiO. Cell lines and primary
cells (30,000 cells in 100 l for each data point) were treated with or without Isotype/CD3,
nanoTCEs, or nanoMuTEs (3.7 nM) for two hours at 37°C. In some cases (for mimicking
antigen downregulation), cells were treated with 33.3 nM of anti-BCMA, CS1, and/or CD38
antibody of the same clone for one hour prior to the two-hour treatment with nanoTCEs or
nanoMuTEs. Following the two-hour treatment with nanoTCEs or nanoMuTEs, the cells were
stained with anti-BCMA, CS1, or CD38 of a different clone for one hour. Then, cells were spun
down, washed with PBS, resuspended in 100 l and analyzed by flow cytometry using
MACSQuant Analyzer 10 with Ex= 488nm and Em= 525/50 nm. Cells were gated using FSC
and SSC and analyzed for MFI of DiO using BD FlowJo Software.

3.2.7 3D Tissue-Engineered Bone Marrow (3DTEBM) Culture
System
The culture’s cellular content can be customized by inclusion of various cell populations. For
testing patient samples, BM mononuclear cells were used as a whole, including the primary
cancer cells and T cells. 3DTEBM was established by crosslinking fibrinogen in patient BM
supernatant using CaCl2, as previously described [287]. Briefly, for testing cell lines, 30,000
cancer cells were combined with 30,000 T cells; for primary cells 100,000 BM mononuclear
cells were used as whole. Cells were suspended in BM supernatant which was then crosslinked
with CaCl2 to form the 3D matrix. The 3DTEBM was supplemented with media on top and
incubated at 37°C for 4 days. At time of analysis, the scaffolds were digested with collagenase
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(Gibco, Life Technologies) for two hours at 37°C; cells were retrieved, washed, and subjected to
flow cytometry analysis.
For the development of antigen-less populations, the above procedure was followed, and
the remaining cells were incubated with APC-anti-BCMA, APC-anti-CS1, or APC-anti-CD38
antibodies in 4°C for one hour; then washed, spun down, resuspended in 100 l and analyzed by
flow cytometry using MACSQuant Analyzer 10 with Ex= 635nm and Em= 655-730 nm. Cells
were gated using FSC and SSC and analyzed for MFI of APC using BD FlowJo Software.

3.2.8 Cell Survival
Cell lines (prelabeled with fluorescent tracer DiO) and primary cells were incubated with T cells
in 3DTEBM and treated with or without Isotype/CD3, nanoTCEs, or nanoMuTEs at a
concentration of 3.7 nM for 4 days. Before digestion of the matrix, 5 μL of counting beads
(Miltenyi Biotec) were added to the culture. The matrix was then digested, cells were retrieved,
and analyzed by flow cytometry using MACSQuant Analyzer 10. For cell lines, the number of
tumor cells analyzed as DiO+ cells and normalized to the number of counting beads using BD
FlowJo Software. For primary cells, MM cells were identified as CD38+/CD3-/CD14-/CD16/CD19-/CD123-, as previously described [288], and the number of MM primary cells was
normalized to the number of counting beads using BD FlowJo Software. For the analysis of WM
killing without T cells, the above procedure was mimicked except without including T cells in
3DTEBM.

3.2.9 Activation of T cells
Cells were in 3DTEBM and treated with or without Isotype/CD3, nanoTCEs, or nanoMuTEs at a
concentration of 3.7 nM for 4 days. Then, cultures were digested, and the cells were retrieved
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and incubated with PE anti-CD3, FITC anti-CD4, Violet anti-CD8, and APC anti-CD69
antibodies for one hour in 4°C, washed with PBS, spun down, and suspended in PBS again.
These samples were analyzed by flow cytometer using MACSQuant Analyzer 10 with Ex= 488,
488, 405, and 635 nm and Em= 585/40, 525/50, 450/50, 655-730 nm, respectively. Cells were
gated using FSC and SSC followed by double positive CD3+/CD4+ or CD3+/CD8+, both of
which were analyzed for % of cells positive for CD69 using BD FlowJo Software.
For cytokine secretion, the supernatant was kept and the 3DTEBM was digested for two
hours using collagenase following the four-day incubation period. Once the 3DTEBM was
digested and samples were spun down, the supernatant (with collagenase) was then added to the
supernatant collected earlier. Subsequently, the samples were analyzed for cytokine presence
following the manufacturer’s protocol and scanned using the InnoScan 710 microarray
fluorescence scanner (Innopsys) by the manufacturer of the cytokine array.

3.2.10
NanoTCE/nanoMuTE and T cell biodistribution, tumor
efficacy, and survival in vivo
For all animal studies, mice were randomized into groups and no blinding was done in this study.
For biodistribution, human MM.1S-CBR cells (2x106/mouse) were injected IV to NSG mice to
generate the MM tumor models. PBMCs were isolated from healthy human donors using Ficoll
centrifugation and subsequently separated for T cells using a human Pan T cell isolation kit
(Miltenyi Biotec), as previously described [281]. T cells (5x106/mouse) were stained with calcein
violet and injected IV to each mouse three weeks following propagation of the MM cells. One
hour post T cell injection, mice were treated IV with Isotype/CD3, nanoTCEs, or nanoMuTEs
stained with DiD (.5 mg/mouse). Organs were extracted 24 hours later and analyzed via flow
cytometry.
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For tumor efficacy and survival, human BCWM.1-Luciferase cells or MM.1S-CBR cells
(2x106/mouse) were injected IV to NSG mice to generate the WM or MM tumor models,
respectively [289]. T cells (5x106/mouse) were injected IV to each mouse 7 days after the
injection of tumor cells. One hour post T cell injection, mice were treated IV with Isotype/CD3,
nanoTCEs, or nanoMuTEs (.5 mg/mouse), and weekly thereafter.
For tumor progression, mice were imaged weekly using bioluminescent imaging (BLI).
Mice were injected with D-luciferin (150 ug/kg) intraperitoneally, and tumor burden was
detected using an IVIS 50 bioluminescence imaging system (PerkinElmer, Waltham, MA) 10
minutes post luciferin injection, and images were analyzed using Living Image 2.6 software
(PerkinElmer). For survival, mice were monitored on a daily basis to record survival.

3.2.11

Gene Expression Analysis

Gene expression data on MM patients were extracted from previously published literature [290]
describing data from 600 newly diagnosed MM patients, in which plasma cells were
subsequently selected using anti-CD138 beads and mRNA gene expression was performed using
the Affymetrix U133 Plus 2.0 microarray platform (Santa Clara, CA) and analyzed using the
Affymetrix Microarray Suite GCOS1.1. BCMA, CS1, and CD38 gene expression was analyzed
and plotted using Python.

3.2.12

Statistical Analyses

All in vitro experiments in this study were independently replicated three times. Sample size for
laboratory animals was estimated using published guidelines [291]. In vitro experiments were
performed in quadruplicates, and in vivo experiments consisted of 7 mice each; data from in
vitro and in vivo experiments were expressed as means ± standard deviation. Data normality was
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analyzed using residuals, and variance similarity across groups were also analyzed by examining
the expected variance of each group. Statistical significance was analyzed using a Student’s ttest, one-way, or two-way analysis of variance (ANOVA). Log-rank test was used to compare
the Kaplan Meier curves. P values less than 0.05 were used to indicate statistically significant
differences.

3.3 Results and Discussion
We have developed nanoTCEs, which are liposomes decorated with anti-CD3 mAbs targeting T
cells, and mAbs targeting the cancer antigen (Figure 4A). We hypothesized that the liposomal
nature of nanoTCEs will have a prolonged half-life. We developed liposomes with or without
stealth PEGylation conjugated to these anti-CD3 and anti-CD20 mAbs (CD20/CD3 nanoTCEs)
(Figure 4B). We chose to target CD20 for targeting WM cells, since CD20 has been routinely
and successfully used as a therapeutic target for WM [292, 293]. Non-PEGylated nanoTCEs
improved the half-life to about 36 hours, while the PEGylated nanoTCEs had even a longer halflife of about 60 hours (Figure 4C). Therefore, we adopted the PEGylated nanoTCEs formulation
for all upcoming experiments. The longer half-life enabled administration of the nanoTCEs once
a week as an intravenous (IV) bolus injection for in vivo experiments. Clinically, the improved
pharmacokinetic profile will be translated into a more convenient dosing regimen and therefore a
dramatic improvement in the patient’s quality of life and decrease risk of infections related to
continuous infusion. Other solutions that have been established to circumvent the low
pharmacokinetic profile include supplementing BTCEs with an Fc receptor or an anti-human
serum albumin binding construct [294, 295]; both methods prevent the rapid elimination and
degradation of BTCEs by the neonatal Fc receptor [296, 297]. There are currently multiple
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ongoing clinical trials testing these newly designed BTCEs for efficacy and toxicity [240, 298301].
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Figure 4. Development of nanoparticle T cell engagers. A. Schematic of classic BTCEs, nanoparticle T
cell engagers, and the utilization of nanoTCE to engage T cells to cancer cells. B. A scheme of the
production of the nanoTCE using thin-film evaporation method, followed by conjugation of mAbs of
choice such as anti-CD20 and anti-CD3. C. The pharmacokinetic profile of nanoTCEs with or without
PEGylation in vivo.
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Figure 5. Development of nanoTCEs for WM. A. RMFI and percent of CD20 protein expression on the
surface of WM cells. B. The effect of the number of anti-CD20 mAbs conjugated to the liposome on the
binding of the nanoTCEs to BCWM.1 cells, and the effect of the number of anti-CD3 mAbs conjugated to
the liposome on the binding of the nanoTCEs to T cells. C. Binding of Isotype/CD3 and CD20/CD3
nanoTCEs to WM cells. Two-sided student t-test was used; statistical significance (p<.05) between
CD20/CD3 and Isotype/CD3 was indicated by placing an asterisk.

First, we validated the use of CD20 as a target for the treatment of WM. We measured
the percent of WM cells that express CD20. For both WM cell lines, CD20 is highly expressed
and on approximately 90% of cells (Figure 5A). We then investigated the effect of the number
of antibodies conjugated to the liposome. Increasing the number of antibodies conjugated to the
liposomes did not increase the binding of the nanoTCEs to WM or T cells, which is shown in
Figure 5B. Therefore, for all the upcoming experiments, we developed nanoTCEs with one CD3
and one CD20 mAb per liposome. We then tested the binding of the CD20/CD3 nanoTCEs to
WM cells, compared to isotype and CD3 conjugated nanoTCEs (Isotype/CD3). The CD20/CD3
nanoTCEs bound to the WM cells about 50-fold greater than Isotype/CD3 nanoTCEs (Figure
5C).
To demonstrate the therapeutic efficacy of the nanoTCEs, we used our 3D Tissue
Engineered Bone Marrow (3DTEBM) model [287] (Figure 6A), in which we used primary BM
aspirates from patients to develop a 3D culture of the malignant BM niche. The model is
developed using all the cells in the tumor microenvironment; not only tumor cells, but also other
accessory cells including T cells. We used the BM supernatant from patients to create the 3D
matrix by crosslinking fibrinogen naturally found in the marrow; the cellular fraction is also reintroduced into the scaffold. The 3DTEBM recapitulates cellular structures and oxygen gradients
of the BM niche and allows proliferation of primary cells from various hematologic
malignancies (such as WM and MM). It can be also used with cell lines in combination with the
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tumor microenvironment (without cancer cells) isolated from patients. We suggest this model as
an optimal model for testing the effect of T cell-based immunotherapies in vitro.
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Figure 6. WM killing and T cell activation with nanoTCEs in vitro. A. A scheme of 3DTEBM
cultures used to determine the effect of nanoTCEs on T cell activation and cancer cell killing in vitro. B.
The effect of Isotype/CD3 and CD20/CD3 nanoTCEs on the killing of WM cells with T cells (n=4). C.
The effect of Isotype/CD3 and CD20/CD3 nanoTCEs on the expression of CD69 on CD4+ and CD8+ T
cells as a marker of T cell activation (n=3). Two-sided student t-test was used; statistical significance
(p<.05) between CD20/CD3 and Isotype/CD3 was indicated by placing an asterisk.
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Figure 7. The Effect of Isotype and CD20 nanoTCEs on the killing of WM cells without T cells.

We tested the effect of CD20/CD3 nanoTCEs on the survival of WM cells in the
3DTEBM. CD20/CD3 nanoTCEs induced 60-70% killing of WM cells, while the Isotype/CD3
nanoTCEs did not induce any killing whatsoever (Figure 6B). We ensured that the MM cell lysis
seen with nanoTCEs was T-cell mediated by incubating WM cells and nanoTCEs or
Isotype/CD3 without T cells and observed no killing of WM cells as seen in Figure 7. In
addition, we tested the activation of T cells by nanoTCEs in the 3DTEBM. CD69 expression, as
a marker of T cell activation, in CD4 and CD8 T cells (Figure 6C) was higher after treatment
with CD20/CD3 nanoTCE compared to Isotype/CD3. Moreover, the CD8 T cells showed higher
activation compared to CD4 T cells. Secretion of cytokines is a hallmark of T cell activation.
Figure 8 shows the cytokine secretion of T cells following their activation with CD20/CD3 and
Isotype/CD3 nanoTCEs in the 3DTEBM. The presence of IL-2, IL-6, IL-10, TNF-α, and IFN-γ
is significantly greater when treated with CD20/CD3 compared to Isotype/CD3. These results
indicate that the CD20/CD3 nanoTCEs are specific to WM cells and that the effect is only
mediated via T cell engagement.
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Figure 8. Cytokine secretions following treatment of WM cells with Isotype and CD20 nanoTCEs.

To demonstrate the therapeutic efficacy in vivo, we chose an aggressive xenograft WM
model by injecting BCWM.1 cells IV (with humanized T cells), that kills the mice in less than 3
weeks following injection, if not treated; this represents the clinically aggressive/relapsed form
of the disease. Mice treated with Isotype/CD3 nanoTCEs showed fast tumor progression and
death of the entire cohort within 21 days. In contrast, mice treated with WM-targeting
CD20/CD3 nanoTCE showed slower tumor progression at days 14 and 21, a significant
reduction at day 28 (compared to day 21), and complete eradication of the tumor by day 35
(Figures 9A and B). The entire cohort survived with no signs of disease for as long as two
months, which is when the experiment was stopped (Figure 9C). These results demonstrate that
the CD20/CD3 nanoTCE immunotherapy has an outstanding potential to treat/cure even the most
aggressive forms of WM.
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Figure 9. WM killing and T cell activation with nanoTCEs in vivo. A. Quantitative and B. qualitative
analysis of the effect of Isotype/CD3 and CD20/CD3 nanoTCEs on the progression of WM tumors in
vivo (n=7). C. The effect of Isotype/CD3 and CD20/CD3 nanoTCEs on the survival of WM-bearing mice
(n=3). Log-rank test was used to compare the Kaplan Meier curves; statistical significance (p<.05)
between CD20/CD3 and Isotype/CD3 was indicated by placing an asterisk.
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The second major limitation of BTCEs (and CAR-T cells) is that they are designed to
target only one antigen on cancer cells. Preclinical studies have demonstrated that targeting
multiple antigens by CAR-T cells or BTCEs are still technically challenging [302-306].
Especially in a multi-clonal disease like MM [307-310], these therapies confer the development
antigen-less clones, causing tumor escape and relapse of the disease [271, 272].
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Figure 10. BCMA, CS1, and CD38 Expressions on Primary Multiple Myeloma (MM) and Cell
Lines. A. mRNA gene expressions of BCMA, CS1, and CD38 in a cohort of 600 MM patients (n=600).
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B. RMFI and C. percent protein expression of BCMA, CS1, and CD38 on MM cell lines and three patient
primary cells.

Several antigens were used previously as targets for T cell-based immunotherapy in MM,
including B cell maturation antigen (BCMA), CD38, and SLAMF7 (CS1) [186, 187, 208, 311,
312]. Gene expression analysis of these antigens in MM patients showed that the expression of
each marker was highly variable, emphasizing the heterogeneity of the expression of these genes
in MM patients (Figure 10A). We also tested the surface protein expression of these antigens on
MM cells, which further showed and emphasized the variability and presence of expression
(Figures 10B and C). Such heterogeneous expression presents a challenge for the efficacy of any
immunotherapy that targets any of these antigens as a single target.
Therefore, we developed a nanoparticle that targets multiple cancer antigens
simultaneously by conjugating multiple mAbs against multiple cancer antigens for T cell
engagement (nanoMuTEs; Figure 11A). We hypothesized that nanoMuTEs will target multiple
clones simultaneously, prevent antigen-less tumor escape, and be more efficacious than targeting
individual antigens.
We tested the binding of three different BCMA/CD3, CS1/CD3, and CD38/CD3
nanoTCEs (each targeting one antigen) and BCMA/CS1/CD38/CD3 nanoMuTEs (targeting all
three antigens) to MM cells. Each nanoTCE bound to MM cells more than the Isotype/CD3nanoTCE, in correlation with the surface expression of each antigen; nanoMuTEs showed higher
binding compared to each nanoTCE alone (Figure 11B).
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Figure 11. Development and biological function of nanoparticle Multispecific T cell Engagers
(nanoMuTEs). A. Illustrations of the Isotype/CD3, BCMA/CD3, CS1/CD3, CD38/CD3 nanoTCEs and
BCMA/CS1/CD38/CD3 nanoMuTEs. B. Binding of the nanoTCEs and nanoMuTEs to MM cell lines and
primary cells (n=3). C. The effect of nanoTCEs and nanoMuTEs on the killing of MM cells by T cells
(n=4). One-way and two-way ANOVA was used; statistical significance (p<.05) was indicated using two
symbols (* and #); specifically, * represents significance between the nanoTCE and Isotype/CD3, and #
represents significance between the nanoTCE and nanoMuTE.

We further tested T cell-induced killing of MM cells by nanoTCEs and nanoMuTEs in
the 3DTEBM. Each nanoTCEs induced more MM killing compared to Isotype/CD3, while
nanoMuTEs induced more MM killing compared to each nanoTCE (Figure 11C). We also tested
T cell activation. Activation of CD4 and CD8 T cells (Figures 12Ai and ii, respectively) was
higher after treatment with each nanoTCE compared to Isotype/CD3, while activation after
treatment with nanoMuTEs was higher than each nanoTCE. CD8 T cells showed higher
activation compared to CD4 T cells when treated with any of the nanoTCEs or nanoMuTEs. In
addition, we investigated the presence of cytokines following treatment with nanoTCEs or
nanoMuTEs (Figures 12Bi and ii). The presence of IL-2, IL-6, IL-10, TNF-α, and IFN-γ is
significantly greater when treated with each nanoTCE compared to Isotype/CD3; nanoMuTEs
induced greater secretion than the nanoTCEs.
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nanoMuTE.
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Next, we developed antigen-less clones by testing the effect of nanoTCEs and
nanoMuTEs on the expression of antigens on MM cells (Figure 13A). When treated with
BCMA/CD3, CS1/CD3, or CD38/CD3, the expression of BCMA, CS1, and CD38 in the whole
MM cell population was decreased, respectively (Figure 13B), but not affected by the nanoTCEs
with other targets. The decrease can be attributed to killing of the population with high
expression of the specific antigen or downregulation of the specific antigen on the cells, both of
which contribute to the development of antigen-less populations. In contrast, the treatment with
nanoMuTEs did not generate a population with lower expression of any of the three antigens,
which suggests that treatment with nanoMuTEs will not cause antigen-less tumor escape and
create a better therapeutic strategy.
We next investigated the effect of blocking (as a model for downregulation) of BCMA,
CD38, and CS1 on the binding of nanoTCEs and nanoMuTE to MM cells. The binding of each
of the nanoTCEs was reduced when the antigens on the cells were blocked with the respective
blocking antibody against the antigen that it is targeting. In contrast, no significant decrease of
the binding of nanoMuTEs was observed when treated with any of the antibodies blocking alone;
likely because the binding was facilitated through other antigens. Binding of nanoMuTEs was
decreased when treated with a combination of the three blocking antibodies (Figure 13C). This
demonstrates that downregulation (or loss) of an antigen will reduce the binding (and hence the
efficacy) of the nanoTCE, as observed clinically with the treatment with CAR-T cells and
BTCEs, but did not affect the binding of nanoMuTEs, which creates a better therapeutic strategy.
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following 24 hours in vivo (n=3). B. The effect of nanoTCEs and nanoMuTEs on the progression of MM
tumors in vivo (n=7). C. The effect of nanoTCEs and nanoMuTEs on the survival of MM-bearing mice
(n=7). One-way and two-way ANOVA was used to assess Figure 15A. Log-rank test was used to
compare the Kaplan Meier curves; statistical significance (p<.05) was indicated using two symbols (* and
#); specifically, * represents significance between the nanoTCE and Isotype/CD3, and # represents
significance between the nanoTCE and nanoMuTE.
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Figure 16. Pharmacokinetics of nanoTCEs and nanoMuTEs in vivo.

We also investigated the biodistribution of nanoTCEs/nanoMuTEs and T cells following
24 hours (Figures 14 and 15A, respectively). We see specific accumulation of nanoTCEs and
nanoMuTEs at the tumor site (BM) compared to Isotype/CD3. Consequently, T cells were
specifically engaged to the tumor site following treatment with nanoTCEs or nanoMuTEs
compared to Isotype/CD3. Next, the pharmacokinetic profile of each of the nanoTCEs and
nanoMuTEs was similar to the CD20/CD3 nanoTCEs with a half-life of approximately 50-60
hours (Figure 16). To demonstrate the therapeutic efficacy of the nanoTCEs and nanoMuTEs in
vivo, we used an aggressive xenograft MM model by injecting MM.1S IV (with humanized T
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cells), that kills the mice in less than 4-5 weeks after injection, if not treated, and represents the
clinically aggressive/relapsed form of the disease. Treatment with Isotype/CD3 nanoTCEs
showed fast tumor progression and death of the cohort within 40 days (Figures 15B and 17).
Treatment of each of the nanoTCEs targeting one antigen (BCMA, CS1 or CD38) resulted in
delayed tumor progression and prolonged survival, while the treatment with the nanoMuTEs
induced longer tumor progression delay and resulted in survival of the entire cohort till 55 days
(Figure 15C).
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Our study successfully shows the proof-of-concept of redirecting T cells to cancer using
nanoparticles. The nanoTCEs/nanoMuTEs used for WM and MM were able to induce T cellmediated cancer cell killing. The effect of the CD20/CD3 nanoTCEs for the treatment of WM
was significantly more profound than the nanoTCEs/nanoMuTEs used for MM; CD20/CD3
cured the WM xenograft murine model whereas the nanoTCEs/nanoMuTEs prolonged survival
of MM mice by only 10-20 days. This is, likely, due to the difference in antigen level and
presence on each cancer type; expression of CD20 was prevalent in the vast majority of WM
cells, while the expression of BCMA, CS1 and CD38 was variable on MM. Moreover, the
intensity of the expression of CD20 on WM cells was 2-3 orders of magnitude higher than
BCMA, CS1 and CD38 on MM.
In conclusion, the nanoTCE/nanoMuTE platform uses nanotechnology to provide a
relatively easy-to-make and off-the-shelf solution to circumvent the major limitations of the
current immunotherapy technologies (CAR-T cells and BTCEs). It takes advantage of the
established high specificity of mAbs to better navigate the robust immune response to eliminate
cancer. In this instance, it would be easy to modify this system to generate a new nanoTCE as an
immunotherapy to target any cancer type by using existing or new mAbs that have the ability to
specifically bind to the cancer cells of interest. The flexibility of the nanoparticle-based immunoengaging technology provides a general platform with groundbreaking translational potential for
developing easy-to-make, specific, and efficacious immunotherapy for cancer in general.
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Chapter 4: Nanoparticle T cell Engagers for the
Treatment of Acute Myeloid Leukemia
4.1 Introduction
AML is the most common type of leukemia and characterized by the overproduction of
immature myeloid stem cells in the bone marrow that has a 5-year survival rate of around 25%
[313, 314]. The survival curves for AML patients have remained stagnant in the past decades due
to the lack of newly approved therapies for AML. However recently, novel therapeutics and
technologies are actively being developed and have shown promising results in preclinical and
clinical settings [315-317].
Exciting immunotherapy technologies that are being investigated for AML including
CAR-T cells and bispecific T cell engagers (TCEs). CAR-T cells are autologous T cells that have
been virally transfected to express an engineered CAR construct, containing a synthesized
fragment that targets the desired surface antigen on the target cell. Several studies have shown
promising preclinical and clinical results with the use of this technology [318]. The main
disadvantages of this technology relative to traditional therapies include toxicity, the long-term
safety profile of the viral vector, the need to perform quality control testing frequently
throughout the production of CAR-T cells, the high costs associated with this technique due to
the need of extensive labor and expensive facility equipment, complex production, and the
inability to target multiple tumor antigens with one CAR-T cell [275, 319].
In addition to CAR-T cells, T cell-based therapy can be pursued with TCEs. TCEs
consists of two single chain variable fragments which are connected by a protein linker. One of
the domains recognizes a tumor-associated surface antigen, while the other recognizes the T cell
using the CD3 receptor [320]. This enables the TCE to redirect the T cell to the tumor and induce
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subsequent activation and expansion of the T cell. TCEs have exploited the use of endogenous T
cells while also demonstrating high potency and efficacy against tumor cells [217, 321, 322].
This immunotherapeutic option has been shown to be successful for both solid and liquid tumors
but is mostly known for the treatment of hematological malignancies [323]. TCEs demonstrate
high potency and efficacy against tumor cells and exploit the use of endogenous T cells,
circumventing the limitation of genetically engineering extracted patient T cells to express
CARs. The disadvantages of TCEs, however, include toxicity, expensive costs with regards to its
labor and production, complex production, short pharmacokinetics, and the inability to target
multiple cancer surface markers [324, 325].
We have previously developed a nanoparticle-based T cell engagers (nanoTCEs)
technology that is based on conjugation of two monoclonal antibodies to the surface of a
liposomal nanoparticle; one antibody is against a cancer antigen and the other is against the CD3
receptor in T cells [265]. NanoTCEs utilize existing monoclonal antibodies which we conjugate
to the surface of a nanoparticle, therefore taking advantage of the high specificity of existing
monoclonal antibody-therapies, to engage and direct the potency and robust response of the
immune system (T cells). NanoTCEs have been shown to circumvent the disadvantages of both
CAR-T cells and TCEs; prolong pharmacokinetic profile, use endogenous T cells, and target
multiple tumor and immune cell antigens while also inducing T cell activation and T cellinduced cancer cell lysis in vitro and in vivo. In addition, nanoTCEs are simple to make; in
which the production of activated nanoparticle and the chemical conjugation of existing and
clinically proven antibody against a specific disease takes only few hours. Therefore, the
nanoTCE technology provides an easy to make platform for development of T-cell engaging
immunotherapy using any existing anti-cancer monoclonal antibody.
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In the past, CD33 has been the target of immunotherapies for AML due to its presence on
the majority of AML cells, and its expression correlates with stage of disease [314]. Therapy
options that have used CD33 as a target and have been rendered successful includes the
antibody-drug conjugate, gemtuzumab ozogamicin [326]. CD33-targeted TCEs in the realm of
AML have also been proven to be effective and safe ex vivo, and these studies have led to the
creation of a phase I clinical study with Amgen’s TCE, AMG 330 (NCT02520427) [327]. In this
study, we sought to create a nanoTCE targeted to CD33 for the treatment of AML.

4.2 Methods
4.2.1 Materials and Reagents
Antibodies and Pan T Cell Isolation Kits were purchased from Miltenyi Biotec (Bergisch
Gladbach, Germany). RPMI-1640, .25% trypsin, L-glutamine, and penicillin-streptomycin were
purchased from Corning (Corning, NY). Fetal bovine serum, lipophilic tracers, collagenase, and
counting beads were purchased from Life Technologies (Carlsbad, CA). 1,2-dipalmitoyl-snglycero-3-phosphocholine (DPPC), 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N[amino(polyethylene glycol)-2000] (DSPE-PEG2000), and membranes were purchased from
Avanti Polar Lipids (Alabaster, AL). Cholesterol was purchased from Millipore Sigma
(Burlington, MA). Streptavidin conjugation kit was purchased from Abcam (Cambridge, United
Kingdom). Mice were NCG (strain: 572), female, 50-56 days old, and purchased from Charles
River (Wilmington, MA), and all experiments using these rodents were in compliance with the
Institutional Animal Care and Use Committee at Washington University.
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4.2.2 Cells
K052, MOLM-14, NOMO-1, and THP-1 were all obtained from the lab of John DiPersio.
Normal donor peripheral blood mononuclear cells (PBMCs) were isolated from healthy donors
using Ficoll and separated for T cells using a Pan T cell kit. Cell lines were cultured in RPMI1640 supplemented with 10% fetal bovine serum, 2 mM of L-glutamine, and 1% penicillinstreptomycin and cultured in NuAire water jacket incubators (NuAire, Plymouth, MN) at 37 °C
and in 5% CO2.

4.2.3 Creation of nanoTCEs
The procedure of making nanoTCEs has been described [265]. Briefly, nanoTCEs were made up
of three components: cholesterol, DPPC, and DSPE-PEG2000 with a mass ratio equivalent to 30:
65: 5, respectively. Lipids were mixed and solubilized in chloroform and evaporated. The film
was then hydrated, and the resulting suspension was extruded using an extruder with 100 nm
polycarbonate membranes [283, 328]. The biotinylated antibodies were conjugated to the
liposomes using streptavidin and biotin reaction [289]. Malvern Zetasizer Nano ZS90 (Malvern,
Worcestershire, United Kingdom) was used to determine zeta potential, diameter, and
polydispersity index.

4.2.4 Protein Expression
Cells were incubated with anti-CD33 APC antibody in 4°C for one hour, washed, and analyzed
by flow cytometry using MACSQuant Analyzer 10 with an Ex/Em of 635/655-730 nm. Cells
were gated using forward and side scatter and analyzed for relative mean fluorescent intensity
(MFI) of APC using BD FlowJo Software [285, 286].
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4.2.5 Liposomal Binding
Each nanoTCE was stained with a fluorescent tracer DiO. Cell lines and T cells were treated
with Isotype/Isotype or CD33/CD3 nanoTCEs (3.7 nM) for two hours at 37°C. Cells were spun
down, washed, and analyzed by flow cytometry with Ex/Em of 488/ 525±25 nm. Cells were
gated using forward and side scatter and analyzed for MFI of DiO using BD FlowJo Software.

4.2.6 Activation of T cells in vitro
Cells were cultured in the 3D tissue engineered bone marrow (3DTEBM) [287] and treated with
Isotype/CD3 or CD33/CD3 nanoTCEs at a concentration of 3.7 nM for 4 days. Then, cultures
were digested, and cells were retrieved and incubated with anti-CD3 PE, anti-CD4 FITC, antiCD8 Violet, and anti-CD69 APC antibodies for one hour in 4°C. These samples were analyzed
by flow cytometer with Ex/Em of 488/585±20, 488/525±25, 405/450±25, and 635/655-730 nm,
respectively. Cells were gated using forward and side scatter followed by double positive
CD3+/CD4+ or CD3+/CD8+, both of which were analyzed for % of cells positive for CD69
using BD FlowJo Software.

4.2.7 T cell-mediated Killing of AML in vitro
Cell lines (pre-labeled with DiO) were incubated with T cells in the 3DTEBM and treated with
Isotype/CD3 or CD33/CD3 nanoTCEs at a concentration of 3.7 nM for 4 days. Before digestion
of the matrix, counting beads were added to the culture. The matrix was then digested, cells were
retrieved, and analyzed by flow cytometry. Number of AML cells were analyzed as DiO+ cells
and normalized to the number of counting beads using BD FlowJo Software.
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4.2.8 T cell-mediated Killing of AML in vivo
Mice were randomized into groups and no blinding was done in this study. Human THP-1 CBR
cells (1x106/mouse) were injected intravenously, and T cells (5x106/mouse) were injected
intravenously seven days post-injection of AML cells. One hour following injection of T cells,
mice were treated intravenously with Isotype/CD3 or CD33/CD3 nanoTCEs (0.5 mg/mouse) and
weekly thereafter for four weeks. These mice were then imaged weekly using bioluminescent
imaging. Mice were injected with D-luciferin (150 ug/kg) intraperitoneally, and tumor burden
was detected using an IVIS 50 bioluminescence imaging system (PerkinElmer, Waltham, MA)
10 minutes post-luciferin injection, and images were analyzed using Living Image 2.6 software
(PerkinElmer). Mice were monitored on a daily basis to record survival.

4.2.9 Statistical Analyses
All experiments were independently replicated three times and performed in quadruplicates, and
animal experiments consisted of seven mice per group; data from in vitro and in vivo
experiments were expressed as means ± standard deviation. Statistical significance was analyzed
using a Student’s t-test, one-way, or two-way analysis of variance. Log-rank test was used to
compare the Kaplan Meier curves. P-values less than 0.05 were used to indicate statistically
significant differences.

4.3 Results and Discussion
CD33 is a valuable target for the treatment of AML, therefore, we first validate the presence of
the marker in our experimental setup. We measured the fluorescent intensity and percent of
CD33 in four different AML cell lines. For all cell lines, CD33 was expressed in high levels
(Figure 18A) and uniformly on 90 – 100% of the cells (Figure 18B).
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Figure 18. CD33 expression on AML cell lines. A. Mean fluorescent intensity and B. percent expression
on K052, MOLM-14, NOMO-1, and THP-1.

Once we validated CD33 as a target in our systems, we developed CD33/CD3 nanoTCEs
for the treatment of AML and used Isotype/CD3 nanoTCEs as control. We characterized the
physicochemical properties of these nanoTCEs such as diameter, polydispersity index, and zeta
potential which are shown in Table 4. We found that the size of the nanoTCEs was about 140
nm, with low polydispersity index indicating the uniformity of the particle size, and with close to
neutral net charge.
Table 4. Parameters for CD33 nanoTCE.
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Figure 19. Development of nanoTCEs for AML. A. Schematic of CD33/CD3 nanoTCEs. Liposomal
binding of Isotype and CD33/CD3 nanoTCEs to B. T cells and C. AML cell lines.

A schematic of the nanoTCEs is shown in Figure 19A. The CD33/CD3 nanoTCEs bound
preferentially to the T cells and AML cell lines which are shown in Figures 19B and 19C.,
respectively, compared to Isotype. To demonstrate the therapeutic efficacy of nanoTCEs in vitro,
we used our 3DTEBM model, in which is a 3D cell culture that mimics the leukemic bone
marrow niche, in which it recapitulates the tumor microenvironment and drug resistance better
than classic 2D cultures [265]. We investigated the effect of nanoTCEs on activation of T cells
and T cell-mediated killing of AML cell lines. In Figure 20A and 20B, activation of T cells was
observe as increase in CD69 upregulation in CD4 and CD8 T cells, respectively, following coculture of T cells with AML cell lines in the presence of CD33/CD3 nanoTCEs, but not
Isotype/CD3 TCEs. We have shown previously that the nanoTCE is not able to activate T cells
alone; this is shown by the use of the Isotype/CD3. T cells do not activate following the binding
of the nanoTCE alone. It only works following the engagement of the T cell and the target cell
via nanoTCE which aligns with the kinetic segregation model for T cell receptor triggering [203,
265]. Consequently, no T cell-mediated killing of AML cells was observed following treatment
with Isotype/CD3 TCEs, while 50-75% killing was observed following treatment with
CD33/CD3 nanoTCEs (Figure 20C).
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Figure 20. Efficacy of CD33 nanoTCEs in vitro. The effect of Isotype/CD3 and CD33/CD3 nanoTCEs
on activation of A. CD4 and B. CD8 T cells, and on C. survival of AML cell lines.

To demonstrate the therapeutic efficacy of nanoTCEs in vivo, we injected human AML
THP-1 cells genetically engineered to express luciferase in an NCG immunocompromised mice.
Then we injected human primary T cells at Day 7 to humanize the T cells in the mouse and
treated with nanoTCEs weekly thereafter. Mice treated with Isotype/CD3 TCEs had high tumor
burden and experienced 60% death at Day 62, and the whole cohort died around Day 67. In
contrast, CD33/CD3 nanoTCE-treated group had significantly lower tumor burden at all time
points (not including Day 6), and 100% of the cohort was alive while all the Isotype/CD3 cohort
was dead on Day 66 (Figure 21A and 21B).
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Figure 21. Efficacy of CD33 nanoTCEs in vivo. A. Tumor progression and B. percent survival of mice
treated with Iso-type/CD3 or CD33/CD3 nanoTCEs.

We have demonstrated the successful use of our nanoTCE for the treatment of AML. The
nanoTCE was able to target CD33, a very abundant and relevant marker on AML, to induce
cytotoxic activity [314]. The CD33/CD3 nanoTCE bound preferentially to AML and T cells; this
enables specific binding to only these cells and prevents binding to other hematopoietic cells to
reduce off-target toxicities. T cell activation and T cell-mediated AML cell lysis was induced
following the use of the nanoTCEs in vitro and in vivo. This shows that the CD33 nanoTCE is a
potent and efficacious immunotherapy treatment for AML which circumvents current limitations
of TCEs including the laborious and complex procedures that are involved in producing TCEs.
The uniqueness of our nanoTCE technology allows the creation of an immunotherapeutic
technique that is simple, reproducible, and quick to make which are all important traits to have
while pursuing an immunotherapy option for AML.
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4.4 Conclusions
All in all, the nanoTCE platform shown here uses nanoparticles to create a relatively simple,
reproducible, and off-the-shelf solution to overcome the major limitations of current
immunotherapy techniques such as TCEs and CAR-T cells. The CD33 nanoTCE targets each
antigen with the high specificity of monoclonal antibodies which enables the creation of a more
robust and customizable immunotherapy technology to take advantage of the immune system for
an effective response. Our system enables the customization of the nanoTCE as an
immunotherapy with the use of existing monoclonal antibodies for the targeting of any desired
cancer or immune cell antigen. This simple, customizable, specific, translational, and efficacious
nanoTCE platform provides the flexibility to engage any immune cell for the treatment of the
cancer of interest.
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Chapter 5: Liposomal Phytohemagglutinin: In Vivo T
Cell Activator as a Novel Pan-Cancer Immunotherapy
T cell-based immunotherapy is a promising approach for manipulating T cells to combat disease.
Multiple clinical trials are investigating different aspects of T cell immunotherapy and have been
rendered successful with impressive clinical outcomes. Examples of T cell immunotherapy
include chimeric antigen receptor (CAR)-T cells which are T cells extracted from the patient,
genetically engineered with a CAR vector that targets a specific antigen on a target cell, activated
and multiplied, and finally injected back into the patient [317]. CAR-T cells are highly activated
and eliminate the target cells in one single injection; however, there are many limitations to this
immunotherapeutic approach such as its complex and tedious production; expensive cost due to
the fact that labor and equipment needed are highly costly; requires frequent quality control
testing throughout production, the long-term safety profile of the viral vector, inability to target
multiple targets, and toxicity [275, 319].
A solution that circumvents most of the limitations of CAR-T cells are bispecific T cell
engagers (TCEs). TCEs are two single chain variable fragments connected by a protein linker
which bind the target cell and T cell by using the desired cell surface antigen and CD3,
respectively [317]. TCEs are highly efficacious and activate T cells endogenously which
eliminates the need to genetically engineer extracted primary T cells. However, there are
disadvantages to using TCEs such as short pharmacokinetic half-life, requires extensive labor for
tedious production, inability to target multiple targets, and toxicity [324, 325]. In addition, a
major disadvantage TCEs have is that their T cell activation and persistence is much weaker than
CAR-T cells, which is why CAR-T cells have a much greater anti-tumor response compared to
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TCEs [329]. Therefore, alternative solutions to induce greater activation and persistence of T
cells during TCE immunotherapy.
Methods to activate T cells include the use of small molecules and lectins, such as
phorbol 12-myristate 13-acetate (PMA), ionomycin, concanavalin A, and phytohemagglutinin
(PHA) [330], are commonly used for research purposes ex vivo, but not in vivo [331]. PMA and
ionomycin stimulate T cells by activating protein kinase C [332], however their use is limited by
their carcinogenic potential [333, 334]. Concanavalin A and PHA, both lectins, stimulate T cells
by binding to glycoproteins on the T cell receptor [332, 335, 336]; however, PHA stimulates T
cells at lower concentrations and induces greater T cell activation compared to concanavalin A
[337]. Yet, PHA has not been used to activate T cells in vivo, for immunotherapy, due to its
biological instability and toxicity. The instability stems from its protein-nature, which causes its
degradation and short bioavailability profile in the blood [216], and toxicity (agglutination of red
and white blood cells) leading to death [336]. Therefore, in order to take full advantage of PHA
for the use as an immune activator, an approach of circumventing the limitations of PHA while
also preserving function is needed. In this study, we report the encapsulation of PHA in a
liposome to increase stability, reduce toxicity, and create an immunotherapeutic that is able to
activate T cells for the use in future immunotherapies to circumvent current obstacles in
immunosuppression and T cell exhaustion.
First, we created liposomes using three types of lipids: DPPC, cholesterol, and 16:0
PEG2000 PE at a mass ratio equal to 60:30:10, respectively. These lipids were then prepared as
previously published [265, 283, 328]. In brief, the lipids were dissolved in chloroform,
evaporated, hydrated with PHA in PBS and extruded as shown in Figure 22A.

87

PHA

A

Hydration and
Extrusion

Evaporation
Lipid
Solution

T cell Activation

C

*

120
100

*

80

120

Survival of T cells
(% of Control)

B

Lipid
film

60
40
20
0

80
60
40
20
0

0

0.1
PHA (mg/mL)

1

0

D

0.1
PHA (mg/mL)

1

E
125

100

100

80

Survival

PHA in Blood
(Fold of .25 hours)

100

75
50

*

25

60

*
*

40
20
0

0
0.25

2

4
8
Time (hrs)

0
10
25
50
PHA Concentration (mg/kg)

24

88

F

G

0

10

Ctrl

25
Free

50

10

25

50

*

120

MM Survival (% of Control)

T cell Activation (%)

80
70
60
50
40
30
20
10
0

100

*

80

*

60
40
20
0
Free Lipo

Liposomal

Ctrl

PHA Concentration (mg/kg)

PHA

MM alone

H

*

*

Free Lipo
Ctrl

PHA

MM + T cells

I
100

6000
5000

Percent survival

Tumor Progression
(Fold of Day 7)

7000

*

4000

*

3000

*

2000
1000
0

80
60
40
20
0

7

14
Day

21

0

5

10 15 20 25 30 35
Day

Control

Free (10mg/kg)

Liposomal (10mg/kg)

Liposomal (50mg/kg)

100

Percent survival

Figure 80
22. Liposomal Phytohemagglutinin (PHA) Has Similar T Cell Activation, Increases
Pharmacokinetic Profile, and Reduces Toxicity Compared to Free. A. Schematic of creation of
60 PHA. B. Activation of T cells at increasing concentrations of free or liposomal PHA in vitro.
liposomal
C. Survival of T cells at increasing concentrations of free or liposomal PHA. D. Pharmacokinetic profile
40
of free and liposomal PHA. E. Survival of mice at increasing concentrations of free or liposomal PHA. F.
Activation
20 of T cells at increasing concentrations of free or liposomal PHA in vivo. G. Multiple myeloma
(MM) survival at increasing concentrations of free or liposomal PHA. H. Tumor progression for four
groups of0mice with MM burden (control, free – 10 mg/kg, liposomal – 10 mg/kg, and liposomal – 50
0
5
10
15
20
25
30
35
mg/kg). I. Survival for four groups of mice with MM burden (control, free – 10 mg/kg, liposomal – 10
Days
mg/kg, and liposomal – 50 mg/kg).

89

Then, we investigated the ability of the PHA-loaded liposomes to activate T cells
compared to free PHA. Peripheral blood mononuclear cells (PBMCs) were incubated for 24
hours in 0, 0.1, or 1 mg/mL of free or liposomal PHA. CD25 expression on CD3 T cells was
analyzed via flow cytometry, as a marker for activation of T cells. CD25 expression was
increased in correlation with PHA concentration, regardless of its formulation, free or liposomal.
Around 90% of T cells had an increase in CD25 expression when incubated with 1 mg/mL of
free or liposomal PHA (Figure 22B). Next, we examined the effect of PHA on T cell survival, as
a marker for toxicity. PBMCs were incubated for 24 hours with free or liposomal PHA and
analyzed for survival via flow cytometry (Figure 22C). No change in T cell survival was
observed for free and liposomal PHA. These results demonstrate that the liposomal formulation
maintained the desired effect of activation of T cells without inducing additional toxicities in
vitro.
However, we are aware that the main limitation of the use of PHA is not the in vitro/ex
vivo, rather it is the low bioavailability and toxicity in vivo. Therefore, we investigated the effect
of the liposomal formulation on PHA’s pharmacokinetic profile and toxicity in vivo. PHA was
labeled with a fluorescent dye Alexa Fluor 647 (AF647). In brief, 25 mg of PHA was dissolved
in 500 microliters of 0.1 M sodium carbonate, excess of AF647 was added, and left for stirring
for one hour at room temperature, and unbound Alexa Fluor 647 was removed with dialysis. AF647-PHA was used free or encapsulated in liposomes. Free or liposomal AF647-PHA (10 mg/kg)
were injected intravenously to C57BL/6 mice (n=3), and blood serum was analyzed at 0.25, 2, 4,
8, and 24 hours using a fluorescent plate reader (Ex/Em=644/665). As expected, free PHA was
degraded rapidly and had an elimination half-life of around two hours. On the contrary,
liposomal PHA showed a significantly longer half-life of about 50 hours (Figure 22D). These
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results demonstrate that the liposomal formulation of PHA overcame its first limitation of low
biological stability in vivo.
We then investigated the effect of the liposomal formulation on the toxicity of PHA in
vivo. It has been previously reported that PHA-induced death of animals happens within few
hours after injection, and no adverse effects are observed in long term [336]. C57BL/6 mice (n=4
per concentration, per condition) were injected with increasing dosed (0, 10, 25 and 50 mg/kg) of
free and liposomal PHA, and closely monitored for survival for three days. Mice treated with
free PHA showed decline in survival with increasing the PHA concentration; while 10mg/kg did
not show toxicity, 25 mg/kg induced death of 1 of 4 animals, and 50 mg/kg induced death of 3 of
4 animals, over 50% of the group, where the dose escalation was stopped. On the contrary,
liposomal PHA induced no death of any of the treated animals at any of the doses. These results
demonstrate that the liposomal formulation of PHA circumvented the most limiting factor of
PHA use in vivo, in which it improved its toxicity profile dramatically (Figure 22E).
As we showed that the liposomal formulation of PHA improved its stability and toxicity
in vivo, we tested if it maintained the efficacy of PHA in activation of T cells. C57BL/6 mice
(n=4 per concentration, per condition) were injected intravenously with 10, 25, or 50 mg/kg of
free and liposomal PHA, and three days following injection, blood was extracted, and T cells
activation was measured as the downregulation of CD62L expression on CD3+ T cells.
Activated T cells were defined as total CD3 T cells minus the T cells with high expression
CD62L. Free and liposomal PHA both induced T cell activation in a dose-dependent manner,
however, liposomal PHA showed higher T cell activation compared to free PHA at all doses
(Figure 22F). These results demonstrate that the liposomal formulation of PHA not only
overcame the stability and toxicity limitations of PHA in vivo, but also maintained, even
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improved, the efficacy of PHA in activation of T cells, most likely due to the improved
bioavailability in vivo, and not due to other biological mechanisms, since this effect was not
observed in vitro.
We then investigated the effect of free or liposomal PHA on the survival of multiple
myeloma (MM) cells, directly or in directly as an immune activator of T cells. Fluorescently
labeled MM cells (OPM2) as a monoculture, or in co-culture with T cells, were treated in vitro
with 1 mg/mL of free or liposomal PHA for 24 hours, and the survival of MM cells was analyzed
using flow cytometry and normalized using counting beads. Neither free nor liposomal PHA had
any direct effects or toxicity on MM cells when the treatment was performed in the absence of T
cells. However, when co-cultured with T cells, both free and liposomal abolished the MM
survival in vitro (Figure 22G). These results emphasize that the robust effect of PHA is
mediated by T cell activation.
Finally, to demonstrate the efficacy of liposomal PHA as an immune activator for the
treatment of cancer, we tested its efficacy in immunocompetent MM mouse model using
C57BL/KaLwRij mice. One million luciferase-expressing 5TGM1 cells were injected per mouse
(n=20) at Day 0. Mice were randomly divided into 4 groups of five mice each and treated with
intravenous injection once a week, starting at Day 7 post cell injection, of: (a) vehicle control; (b)
the maximal tolerated dose of free PHA which did not cause any deaths in vivo (10 mg/kg); (c) a
comparable dose of liposomal PHA (10 mg/kg); and (d) with the highest tested dose of liposomal
PHA which did not show toxicity in vivo (50 mg/kg), no comparable dose was use of free PHA,
since this induced immediate death of more than 50% of the animals. In Figure 22H, tumor
progression was significantly lower than control for both 10 mg/kg free and liposomal PHA, no
statistical difference was found between free and liposomal PHA. However, the higher dose of
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liposomal PHA (50 mg/kg) abrogated the tumor progression, significantly lower control than 10
mg/kg free and liposomal PHA. The control cohort died within Day 22, 10 mg/kg free and
liposomal PHA had 60% of mice survive past Day 31; whereas 50 mg/kg liposomal PHA-treated
mice had 100% survival up to day 35 (Figure 22I).
In conclusion, liposomal PHA is a promising cancer immunotherapy that manipulates T
cells in situ. Liposomal PHA can be used as a highly effective, stand-alone, T cell
immunotherapy, which in opposite to CAR-Ts and TCEs does not included specific targeting to
a specific tumor, which makes it available for use in pan-cancer fashion. Moreover, unlike CARTs, liposomal PHA can be used off the shelf without over-personalization of the therapy, without
the needs of complex manufacturing and safety concerns. In addition, antigen-targeted T cell
therapies, such as CAR-Ts and TCEs, were previously shown to induce antigen-less tumor
escape and cause relapse of the disease [227, 338-342], therefore, and since it is not targeted
against a single antigen, we expect that the liposomal PHA will not induce antigen-less tumor
escape and relapse of the disease. Further studies are needed to investigate the use of these PHA
liposomes with different tumors and in combination with other T cell therapies, and traditional
chemo and biological therapies.
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